Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 3/20 | 0.58 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.58 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.58 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | PYGB | P11216 | 6/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| B-D-Galactose SCHEMBL9880688 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL10050866 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL2441804 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL13220216 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL18649521 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL8527882 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL23758905 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL17112445 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL21123450 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8CA12 | |
| B-D-Galactose SCHEMBL9820102 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1113 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | claimed |
| US-10960570-B2 | Additives for lignocellulosic composites | HEXION INC. (US) | 2021-03-30 | — | — | US | claimed |
| EP-3198072-B1 | NON-FLUORINATED URETHANE BASED COATINGS | CHEMOURS CO FC LLC (US) | 2020-10-28 | — | — | EP | claimed |
| US-20190270219-A1 | ADDITIVES FOR LIGNOCELLULOSIC COMPOSITES | HEXION INC. | 2019-09-05 | — | — | US | claimed |
| US-10011617-B2 | Isocyanate derived organosilanes | THE CHEMOURS COMPANY FC, LLC (US) | 2018-07-03 | — | — | US | claimed |
| US-8212013-B2 | Phenyl 3,4,6-tri-O-benzyl-2-O-(1,1,2,2-tetramethyl-dimethylene phosphonoyl)- beta -D-thioglucopyranoside; inhibits formation of o-ester by-product resulting from the conventional glycosilation reaction of pyranose compounds of 1,2-trans form, affording 1,2-transglycoside compounds with high selectivity | OTSUKA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | claimed |
| US-20080177049-A1 | Process for Producing 1,2-Trans-Glycoside Compound | GLYTECH, INC. (JP) | 2008-07-24 | — | — | US | claimed |
| EP-1849794-A1 | PROCESS FOR PRODUCING 1,2-TRANS-GLYCOSIDE COMPOUND | Otsuka Chemical Co., Ltd. (JP) | 2007-10-31 | — | — | EP | claimed |
| WO-2007088559-A1 | PROCESS FOR PRODUCING SUBSTITUTED SULPHOXIDES | JUBILANT ORGANOSYS LIMITED (IN) | 2007-08-09 | — | — | WO | claimed |
| EP-1186688-B1 | Hollow fibrous organic nanotube and method for producing the same | NAT INST OF ADVANCED IND SCIEN (JP) | 2005-06-15 | — | — | EP | claimed |
| US-6693178-B2 | HALOGENATED BENZYL ETHER GALACTOPYRANOSIDE, GLUCOPYRANOSIDE, RIBOFURANOSIDE OR XYLOFURANOSIDE DERIVATIVES; STABLE, EASILY REMOVED | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2004-02-17 | — | — | US | claimed |
| US-20020045199-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HULTGREN SCOTT (US) | 2002-04-18 | — | — | US | claimed |
| WO-1998024792-A1 | ANTICOAGULANT GLYCOSIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 1998-06-11 | — | — | WO | claimed |
| EP-0661932-A4 | SPECIFIC EATABLE TASTE MODIFIERS. | BIORESEARCH INC (US) | 1996-06-05 | — | — | EP | claimed |
| EP-0661932-A1 | SPECIFIC EATABLE TASTE MODIFIERS | BIORESEARCH, INC. (US) | 1995-07-12 | — | — | EP | claimed |
| EP-0485517-A1 | SYNTHESIS OF GLYCOSIDES HAVING PREDETERMINED STEREOCHEMISTRY | YALE UNIVERSITY (US) | 1992-05-20 | — | — | EP | claimed |
| US-5041541-A | 5-C-Hydroxymethylhexose Compounds | THE PROCTER & GAMBLE COMPANY (US) | 1991-08-20 | — | — | US | claimed |
| WO-1991002739-A1 | SYNTHESIS OF GLYCOSIDES HAVING PREDETERMINED STEREOCHEMISTRY | YALE UNIVERSITY (US) | 1991-03-07 | — | — | WO | claimed |
| EP-0341062-A2 | Functional sugar substitutes with reduced calories | THE PROCTER & GAMBLE COMPANY (US) | 1989-11-08 | — | — | EP | claimed |
| US-20260137677-A1 | PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2 | TOCRIS COOKSON LTD (GB) | 2026-05-21 | — | — | US | disclosed |
| US-20260109721-A1 | IONIZABLE CATIONIC LIPIDS INCORPORATING SILICON: SYNTHESIS AND LNP FORMULATION | ALDEXCHEM KFT (HU) | 2026-04-23 | — | — | US | disclosed |
| EP-4727929-A2 | 5'-MODIFIED MONOMERS, OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS | Alnylam Pharmaceuticals, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4726101-A1 | WATER REPELLENT COMPOSITION AND METHOD FOR PRODUCING SAME | Daikin Industries, Ltd. (JP) | 2026-04-15 | — | — | EP | disclosed |
| US-20260098377-A1 | FIBER STRUCTURE | DAIKIN INDUSTRIES, LTD. (JP) | 2026-04-09 | — | — | US | disclosed |
| US-20260062633-A1 | EMULSION | QUADRISE INTERNATIONAL LTD (GB) | 2026-03-05 | — | — | US | disclosed |
| EP-4688653-A2 | MANUFACTURING OF HYBRID ORGANIC-INORGANIC SILICA AEROGELS | AEROBEL BV (BE) | 2026-02-11 | — | — | EP | disclosed |
| US-20260008793-A1 | IONIZABLE CATIONIC LIPIDS INCORPORATING SILICON | ALDEXCHEM KFT (HU) | 2026-01-08 | — | — | US | disclosed |
| EP-4673438-A1 | PROTEOLYSIS-TARGETING CHIMERAS | Tocris Cookson Limited (GB) | 2026-01-07 | — | — | EP | disclosed |
| EP-4663716-A1 | WATER REPELLENT COMPOSITION | Daikin Industries, Ltd. (JP) | 2025-12-17 | — | — | EP | disclosed |
| US-12497613-B2 | Modified oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250346778-A1 | FLUORINE-CONTAINING COMPOUND | DAIKIN INDUSTRIES, LTD. (JP) | 2025-11-13 | — | — | US | disclosed |
| EP-4646422-A1 | IONIZABLE CATIONIC LIPIDS INCORPORATING SILICON: SYNTHESIS AND LNP FORMULATION | AldexChem Kft. (HU) | 2025-11-12 | — | — | EP | disclosed |
| US-20250340519-A1 | RADIOLABELLED COMPOUND | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2025-11-06 | — | — | US | disclosed |
| EP-4633738-A1 | CYTOTOXIC COMPOUNDS | Pheon Therapeutics Ltd (GB) | 2025-10-22 | — | — | EP | disclosed |
| EP-4624459-A2 | RADIOLABELLED COMPOUND | Oxford University Innovation Limited (GB) | 2025-10-01 | — | — | EP | disclosed |
| EP-4617341-A1 | WATER REPELLENT COMPOSITION | Daikin Industries, Ltd. (JP) | 2025-09-17 | — | — | EP | disclosed |
| US-20250283066-A1 | METHODS AND COMPOSITIONS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2025-09-11 | — | — | US | disclosed |
| EP-4163350-B1 | WATER REPELLENT COMPOSITION, KIT, WATER REPELLENT FIBER PRODUCT AND METHOD FOR MANUFACTURING SAME | MEISEI CHEMICAL WORKS LTD (JP) | 2025-09-10 | — | — | EP | disclosed |
| EP-3630779-B1 | ANTIBIOTIC RESISTANCE BREAKERS | KING S COLLEGE LONDON (GB) | 2025-09-03 | — | — | EP | disclosed |
| US-12398162-B2 | Guanine analogs as telomerase substrates and telomere length affectors | GERON CORPORATION (US) | 2025-08-26 | — | — | US | disclosed |
| EP-4603635-A1 | FIBER STRUCTURE | DAIKIN INDUSTRIES, LTD. (JP) | 2025-08-20 | — | — | EP | disclosed |
| EP-4598914-A1 | PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2 | Tocris Cookson Limited (GB) | 2025-08-13 | — | — | EP | disclosed |
| EP-4598582-A1 | PROTEOLYSIS-TARGETING CHIMERAS AGAINST THE PAPAIN-LIKE PROTEASE OF SARS-COV-2 | Tocris Cookson Limited (GB) | 2025-08-13 | — | — | EP | disclosed |
| US-20250224411-A1 | MOLECULAR HOPPER | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2025-07-10 | — | — | US | disclosed |
| EP-4581107-A1 | EMULSION | Quadrise International Ltd (GB) | 2025-07-09 | — | — | EP | disclosed |
| EP-4574872-A1 | FLUORINE-CONTAINING COMPOUND | DAIKIN INDUSTRIES, LTD. (JP) | 2025-06-25 | — | — | EP | disclosed |
| EP-4562021-A2 | IONIZABLE CATIONIC LIPIDS INCORPORATING SILICON | AldexChem Kft. (HU) | 2025-06-04 | — | — | EP | disclosed |
| WO-2025104452-A1 | COMPOUNDS FOR USE IN TREATMENT | MITORX THERAPEUTICS LTD (GB) | 2025-05-22 | — | — | WO | disclosed |
| US-20250163159-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-05-22 | — | — | US | disclosed |
| WO-2025090191-A1 | TEXTILE TREATMENT FOR IMPARTING OIL REPELLENCY INCLUDES USE OF A NON-CRYSTALLINE SILICONE – (METH)ACRYLATE COPOLYMER, A CRYSTALLINE POLYMER, AND A BLOCKED ISOCYANATE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2025090190-A1 | TEXTILE TREATMENT FOR IMPARTING OIL REPELLENCY INCLUDES USE OF A SILICONE – (METH)ACRYLATE COPOLYMER AND A URETHANE | DOW SILICONES CORPORATION (US) | 2025-05-01 | — | — | WO | disclosed |
| US-12286657-B2 | Methods and compositions | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2025-04-29 | — | — | US | disclosed |
| US-20250123276-A1 | HIGHLY SENSITIVE IMMUNOASSAY REAGENT AND MEASUREMENT METHOD | PCH Corporation (JP) | 2025-04-17 | — | — | US | disclosed |
| WO-2025052296-A1 | IONIZABLE CATIONIC LIPIDS INCORPORATING SILICON: SYNTHESIS AND LNP FORMULATION | ALDEXCHEM KFT. (HU) | 2025-03-13 | — | — | WO | disclosed |
| EP-4520765-A1 | IONIZABLE CATIONIC LIPIDS INCORPORATING SILICON | AldexChem Kft. (HU) | 2025-03-12 | — | — | EP | disclosed |
| US-12247990-B2 | Molecular hopper | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2025-03-11 | — | — | US | disclosed |
| WO-2025047963-A1 | WATER REPELLENT COMPOSITION | ダイキン工業株式会社 | 2025-03-06 | — | — | WO | disclosed |
| WO-2025047961-A1 | WATER REPELLENT COMPOSITION | ダイキン工業株式会社 | 2025-03-06 | — | — | WO | disclosed |
| CN-113631560-B | Azetidine benzodiazepine dimers and conjugates comprising the same for the treatment of cancer | 麦迪穆有限责任公司 | 2025-02-18 | — | — | CN | disclosed |
| WO-2025023238-A1 | FIBER STRUCTURE | ダイキン工業株式会社 | 2025-01-30 | — | — | WO | disclosed |
| US-12209099-B2 | Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer | MEDIMMUNE LIMITED (GB) | 2025-01-28 | — | — | US | disclosed |
| EP-4488285-A2 | MOLECULAR HOPPER | Oxford University Innovation Limited (GB) | 2025-01-08 | — | — | EP | disclosed |
| WO-2024259190-A2 | 5'-MODIFIED MONOMERS, OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| EP-3824285-B1 | MOLECULAR HOPPER | UNIV OXFORD INNOVATION LTD (GB) | 2024-12-11 | — | — | EP | disclosed |
| US-20240400536-A1 | IDEBENONE DERIVATIVES AND THEIR USE IN TREATING PLANTS | MITORX THERAPEUTICS LTD (GB) | 2024-12-05 | — | — | US | disclosed |
| US-20240383827-A1 | DIFLUOROCARBENE RADIOSYNTHESIS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-11-21 | — | — | US | disclosed |
| WO-2024219501-A1 | GLYCOLIPID DERIVATIVE AS MINCLE LIGAND | 国立大学法人大阪大学 | 2024-10-24 | — | — | WO | disclosed |
| WO-2024200821-A2 | MANUFACTURING OF HYBRID ORGANIC-INORGANIC SILICA AEROGELS | AEROBEL BV (BE) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| WO-2024185707-A1 | FLUORINE-CONTAINING COMPOUND | ダイキン工業株式会社 | 2024-09-12 | — | — | WO | disclosed |
| WO-2024180157-A1 | PROTEOLYSIS-TARGETING CHIMERAS | TOCRIS COOKSON LIMITED (GB) | 2024-09-06 | — | — | WO | disclosed |
| CN-118414150-A | Pharmaceutical composition with enhanced stability characteristics | 阿奎斯蒂弗医疗股份有限公司 | 2024-07-30 | — | — | CN | disclosed |
| US-20240246905-A1 | VINYL ISOCYANIDE COMPOUNDS AS ANTIBACTERIAL AGENTS | UNIVERSITY OF LEICESTER (GB) | 2024-07-25 | — | — | US | disclosed |
| EP-4396174-A1 | IDEBENONE DERIVATIVES AND THEIR USE IN TREATING PLANTS | Mitorx Therapeutics Limited (GB) | 2024-07-10 | — | — | EP | disclosed |
| WO-2024127333-A1 | CYTOTOXIC COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024127332-A1 | CYTOTOXIC COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2024-06-20 | — | — | WO | disclosed |
| EP-4364754-A2 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2024074849-A1 | PROTEOLYSIS-TARGETING CHIMERAS AGAINST THE PAPAIN-LIKE PROTEASE OF SARS-COV-2 | TOCRIS COOKSON LIMITED (GB) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024074848-A1 | PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2 | TOCRIS COOKSON LIMITED (GB) | 2024-04-11 | — | — | WO | disclosed |
| US-20240109916-A1 | CYTOTOXIC AGENTS | PHEON THERAPEUTICS LTD (GB) | 2024-04-04 | — | — | US | disclosed |
| EP-4337635-A1 | VINYL ISOCYANIDE COMPOUNDS AS ANTIBACTERIAL AGENTS | University of Leicester (GB) | 2024-03-20 | — | — | EP | disclosed |
| EP-3612234-B1 | COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE | ADC THERAPEUTICS SA (CH) | 2024-03-13 | — | — | EP | disclosed |
| WO-2024047354-A1 | EMULSION | QUADRISE INTERNATIONAL LIMITED (GB) | 2024-03-07 | — | — | WO | disclosed |
| EP-4317991-A1 | HIGHLY SENSITIVE IMMUNOASSAY REAGENT AND MEASUREMENT METHOD | LSI Medience Corporation (JP) | 2024-02-07 | — | — | EP | disclosed |
| WO-2024023174-A2 | IONIZABLE CATIONIC LIPIDS INCORPORATING SILICON | ALDEXCHEM KFT. (HU) | 2024-02-01 | — | — | WO | disclosed |
| US-20240002379-A1 | ASYMMETRIC CONJUGATE COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2024-01-04 | — | — | US | disclosed |
| US-20230372528-A1 | GLYCOCONJUGATES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2023-11-23 | — | — | US | disclosed |
| US-11813335-B2 | Pyrrolobenzodiazepine-antibody conjugates | MEDIMMUNE LIMITED (GB) | 2023-11-14 | — | — | US | disclosed |
| EP-3938372-B1 | AZETIDOBENZODIAZEPINE DIMERS AND CONJUGATES COMPRISING THEM FOR USE IN THE TREATMENT OF CANCER | MEDIMMUNE LTD (GB) | 2023-10-25 | — | — | EP | disclosed |
| US-20230332348-A1 | SILICONE POLYETHER POLYMER TREATMENTS FOR FIBROUS SUBSTRATES | THE CHEMOURS COMPANY FC, LLC (US) | 2023-10-19 | — | — | US | disclosed |
| US-11779650-B2 | Pyrrolobenzodiazepine-antibody conjugates | MEDIMMUNE LIMITED (GB) | 2023-10-10 | — | — | US | disclosed |
| US-11771775-B2 | Pyrrolobenzodiazepine-antibody conjugates | MEDIMMUNE LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20230302142-A1 | Cytotoxic Agents | Pheon Therapeutics Ltd. (GB) | 2023-09-28 | — | — | US | disclosed |
| EP-4247828-A1 | PROTECTED DISACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE IN THE SYNTHESIS OF ZWITTERIONIC OLIGOSACCHARIDES, AND CONJUGATES THEREOF | Institut Pasteur (FR) | 2023-09-27 | — | — | EP | disclosed |
| US-11746116-B2 | Antibiotic resistance breakers | KING'S COLLEGE LONDON (GB) | 2023-09-05 | — | — | US | disclosed |
| EP-4219638-A1 | MODIFIED NATURAL MATERIAL AND USE THEREOF | Daikin Industries, Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| EP-4218929-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4211192-A1 | SILICONE POLYETHER POLYMER TREATMENTS FOR FIBROUS SUBSTRATES | The Chemours Company FC, LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-11702473-B2 | Site-specific antibody-drug conjugates | MEDIMMUNE LIMITED (GB) | 2023-07-18 | — | — | US | disclosed |
| US-20230220217-A1 | MODIFIED NATURAL MATERIAL AND USE THEREOF | DAIKIN INDUSTRIES, LTD. (JP) | 2023-07-13 | — | — | US | disclosed |
| US-11690918-B2 | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates | MEDIMMUNE LIMITED (GB) | 2023-07-04 | — | — | US | disclosed |
| EP-4188927-A1 | CYTOTOXIC AGENTS | Pheon Therapeutics Ltd (GB) | 2023-06-07 | — | — | EP | disclosed |
| WO-2023092188-A1 | \"COMPOUNDS AND METHODS\ | DemAgtech Pty Ltd (AU) | 2023-06-01 | — | — | WO | disclosed |
| US-11649250-B2 | Pyrrolobenzodiazepine conjugates | MEDIMMUNE LIMITED (GB) | 2023-05-16 | — | — | US | disclosed |
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230120736-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-04-20 | — | — | US | disclosed |
| EP-4163350-A1 | WATER REPELLENT COMPOSITION, KIT, WATER REPELLENT FIBER PRODUCT AND METHOD FOR MANUFACTURING SAME | MEISEI CHEMICAL WORKS, LTD. (JP) | 2023-04-12 | — | — | EP | disclosed |
| WO-2023047104-A1 | DIFLUOROCARBENE RADIOSYNTHESIS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-03-30 | — | — | WO | disclosed |
| US-11612665-B2 | Pyrrolobenzodiazepine-antibody conjugates | MEDIMMUNE LIMITED (GB) | 2023-03-28 | — | — | US | disclosed |
| WO-2023041906-A1 | IDEBENONE DERIVATIVES AND THEIR USE IN TREATING PLANTS | MITORX THERAPEUTICS LIMITED (GB) | 2023-03-23 | — | — | WO | disclosed |
| US-20230053603-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | ADC THERAPEUTICS SA (CH) | 2023-02-23 | — | — | US | disclosed |
| US-20230015617-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| EP-4103727-A2 | PRODUCTION OF GLYCOSYLATED PRODUCT IN HOST CELLS | Inbiose N.V. (BE) | 2022-12-21 | — | — | EP | disclosed |
| EP-4103726-A1 | KDO-FREE PRODUCTION HOSTS FOR OLIGOSACCHARIDE SYNTHESIS | Inbiose N.V. (BE) | 2022-12-21 | — | — | EP | disclosed |
| US-11524969-B2 | Pyrrolobenzodiazepines and conjugates thereof as antitumour agents | MEDIMMUNE LIMITED (GB) | 2022-12-13 | — | — | US | disclosed |
| US-20220389419-A1 | MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| WO-2022238694-A1 | VINYL ISOCYANIDE COMPOUNDS AS ANTIBACTERIAL AGENTS | THE UNIVERSITY OF BATH (GB) | 2022-11-17 | — | — | WO | disclosed |
| EP-3356477-B1 | HYDROPHOBIC EXTENDERS IN FLUORINATED SURFACE EFFECT COATINGS | CHEMOURS CO FC LLC (US) | 2022-11-09 | — | — | EP | disclosed |
| US-11484606-B2 | Pyrrolobenzodiazepine-antibody conjugates | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2022-11-01 | — | — | US | disclosed |
| US-11466032-B2 | Cytotoxic agents | FEMTOGENIX LIMITED | 2022-10-11 | — | — | US | disclosed |
| WO-2022211009-A1 | HIGHLY SENSITIVE IMMUNOASSAY REAGENT AND MEASUREMENT METHOD | 株式会社ＬＳＩメディエンス | 2022-10-06 | — | — | WO | disclosed |
| US-11459485-B2 | Non-fluorinated coating and finish agents | THE CHEMOURS COMPANY FC, LLC (US) | 2022-10-04 | — | — | US | disclosed |
| US-20220306660-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2022-09-29 | — | — | US | disclosed |
| US-20220298161-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN SARL (CH) | 2022-09-22 | — | — | US | disclosed |
| US-20220288221-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2022-09-15 | — | — | US | disclosed |
| EP-2771696-B1 | METHODS MAKING USE OF PANELS OF METABOLITES FOR THE DIAGNOSIS AND DIFFERENTIATION OF NEONATAL ENCEPHALOPATHY | INFANDX AG (DE) | 2022-09-14 | — | — | EP | disclosed |
| EP-4045180-A1 | DEVICE FOR AUTOMATED SYNTHESIS OF OLIGO- AND POLYSACCHARIDES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-08-24 | — | — | EP | disclosed |
| EP-4045182-A1 | MICROWAVE-ASSISTED METHOD FOR SYNTHESIS OF OLIGO- AND POLYSACCHARIDES ON SOLID PHASE | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-08-24 | — | — | EP | disclosed |
| EP-4041248-A1 | MODIFIED OLIGONUCLEOTIDES | Alnylam Pharmaceuticals Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| EP-4039280-A1 | TARGETED PYRROLOBENZODIAZEPINE CONJUGATES | Seagen Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| EP-3612537-B1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LTD (GB) | 2022-07-13 | — | — | EP | disclosed |
| US-11384098-B2 | Pyrrolobenzodiazepine-antibody conjugates | ADC THERAPEUTICS SA (CH) | 2022-07-12 | — | — | US | disclosed |
| US-11370801-B2 | Pyrrolobenzodiazepine conjugates | MEDIMMUNE LIMITED (GB) | 2022-06-28 | — | — | US | disclosed |
| US-11359099-B2 | Hydrophobic extenders in fluorinated surface effect coatings | THE CHEMOURS COMPANY FC, LLC (US) | 2022-06-14 | — | — | US | disclosed |
| EP-3710066-B1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LTD (GB) | 2022-06-08 | — | — | EP | disclosed |
| WO-2022106703-A1 | PROTECTED DISACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE IN THE SYNTHESIS OF ZWITTERIONIC OLIGOSACCHARIDES, AND CONJUGATES THEREOF | INSTITUT PASTEUR (FR) | 2022-05-27 | — | — | WO | disclosed |
| US-20220160905-A1 | FLUORINATION METHOD | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2022-05-26 | — | — | US | disclosed |
| US-20220160881-A1 | AZETIDOBENZODIAZEPINE DIMERS AND CONJUGATES COMPRISING THEM FOR USE IN THE TREATMENT OF CANCER | MEDIMMUNE LIMITED (GB) | 2022-05-26 | — | — | US | disclosed |
| WO-2022079211-A1 | GLYCOCONJUGATES | ADC THERAPEUTICS SA (CH) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022065382-A1 | MODIFIED NATURAL MATERIAL AND USE THEREOF | ダイキン工業株式会社 | 2022-03-31 | — | — | WO | disclosed |
| US-20220098191-A1 | G-A CROSSLINKING CYTOTOXIC AGENTS | Pheon Therapeutics Ltd. (GB) | 2022-03-31 | — | — | US | disclosed |
| WO-2022055884-A1 | SILICONE POLYETHER POLYMER TREATMENTS | THE CHEMOURS COMPANY FC, LLC (US) | 2022-03-17 | — | — | WO | disclosed |
| WO-2022055874-A1 | SILICONE POLYETHER POLYMER TREATMENTS FOR FIBROUS SUBSTRATES | THE CHEMOURS COMPANY FC, LLC (US) | 2022-03-17 | — | — | WO | disclosed |
| US-11274220-B2 | Hydrophobic extenders in non-fluorinated surface effect coatings | THE CHEMOURS COMPANY FC, LLC (US) | 2022-03-15 | — | — | US | disclosed |
| WO-2022023735-A1 | CYTOTOXIC AGENTS | FEMTOGENIX LIMITED (GB) | 2022-02-03 | — | — | WO | disclosed |
| US-20220016261-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2022-01-20 | — | — | US | disclosed |
| EP-2558127-B1 | TARGETED PYRROLOBENZODIAZEPINE CONJUGATES | SEAGEN INC (US) | 2022-01-19 | — | — | EP | disclosed |
| EP-3938372-A1 | AZETIDOBENZODIAZEPINE DIMERS AND CONJUGATES COMPRISING THEM FOR USE IN THE TREATMENT OF CANCER | MedImmune Limited (GB) | 2022-01-19 | — | — | EP | disclosed |
| EP-3939616-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | ADC Therapeutics SA (CH) | 2022-01-19 | — | — | EP | disclosed |
| US-20220008552-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | BLUE OWL OPPORTUNISTIC MASTER FUND I, L.P. (FORMERLY KNOWN AS OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P.) | 2022-01-13 | — | — | US | disclosed |
| US-20220010296-A1 | METHODS AND COMPOSITIONS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2022-01-13 | — | — | US | disclosed |
| EP-3668874-B1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LTD (GB) | 2021-12-22 | — | — | EP | disclosed |
| US-20210380605-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| EP-3917924-A1 | G-A CROSSLINKING CYTOTOXIC AGENTS | Femtogenix Limited (GB) | 2021-12-08 | — | — | EP | disclosed |
| US-20210371413-A1 | POLYCYCLIC AMIDES AS CYTOTOXIC AGENTS | Pheon Therapeutics Ltd. (GB) | 2021-12-02 | — | — | US | disclosed |
| US-11160803-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2021-11-02 | — | — | US | disclosed |
| US-11160872-B2 | Pyrrolobenzodiazepine-antibody conjugates | ADC THERAPEUTICS SA (CH) | 2021-11-02 | — | — | US | disclosed |
| US-20210316006-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2021-10-14 | — | — | US | disclosed |
| US-20210318340-A1 | MOLECULAR HOPPER | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-10-14 | — | — | US | disclosed |
| US-11135303-B2 | Pyrrolobenzodiazepines and conjugates thereof | MEDIMMUNE LIMITED (GB) | 2021-10-05 | — | — | US | disclosed |
| EP-3356476-B1 | HYDROPHOBIC EXTENDERS IN NON-FLUORINATED SURFACE EFFECT COATINGS | CHEMOURS CO FC LLC (US) | 2021-09-22 | — | — | EP | disclosed |
| US-20210284613-A1 | RADIOLABELLED COMPOUND | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-09-16 | — | — | US | disclosed |
| US-20210283141-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2021-09-16 | — | — | US | disclosed |
| WO-2021160828-A1 | KDO-FREE PRODUCTION HOSTS FOR OLIGOSACCHARIDE SYNTHESIS | INBIOSE N.V. (BE) | 2021-08-19 | — | — | WO | disclosed |
| WO-2021160827-A2 | PRODUCTION OF GLYCOSYLATED PRODUCT IN HOST CELLS | INBIOSE N.V. (BE) | 2021-08-19 | — | — | WO | disclosed |
| EP-3579883-B1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | ADC THERAPEUTICS SA (CH) | 2021-08-11 | — | — | EP | disclosed |
| EP-3535336-B1 | COATINGS INCORPORATING NON-FLUORINATED CLEANABILITY ADDITIVES | CHEMOURS CO FC LLC (US) | 2021-08-11 | — | — | EP | disclosed |
| US-20210230395-A1 | SOLID POLYMERIC ARTICLES HAVING HYDROPHOBIC COMPOUNDS INTERMIXED THEREIN | THE CHEMOURS COMPANY FC, LLC (US) | 2021-07-29 | — | — | US | disclosed |
| EP-3849956-A1 | FLUORINATION METHOD | Oxford University Innovation Limited (GB) | 2021-07-21 | — | — | EP | disclosed |
| EP-3847166-A1 | POLYCYCLIC AMIDES AS CYTOTOXIC AGENTS | Femtogenix Limited (GB) | 2021-07-14 | — | — | EP | disclosed |
| EP-3197931-B1 | USE OF NON-FLUORINATED OR PARTIALLY FLUORINATED URETHANES IN COATINGS | CHEMOURS CO FC LLC (US) | 2021-07-14 | — | — | EP | disclosed |
| EP-3835322-A2 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| US-20210171637-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2021-06-10 | — | — | US | disclosed |
| EP-3824285-A1 | MOLECULAR HOPPER | Oxford University Innovation Limited (GB) | 2021-05-26 | — | — | EP | disclosed |
| US-11008439-B2 | Solid polymeric articles having hydrophobic compounds intermixed therein | THE CHEMOURS COMPANY FC, LLC (US) | 2021-05-18 | — | — | US | disclosed |
| US-20210137940-A1 | PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2021-05-13 | — | — | US | disclosed |
| EP-3313453-B1 | METHOD FOR IMAGING ARTHRITIS | GUYS AND ST THOMAS HOSPITAL NHS FOUND TRUST (GB) | 2021-04-28 | — | — | EP | disclosed |
| WO-2021074182-A1 | PRODUCTION OF BIOPRODUCT IN A HOST CELL | INBIOSE N.V. (BE) | 2021-04-22 | — | — | WO | disclosed |
| US-20210113587-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2021-04-22 | — | — | US | disclosed |
| US-20210107923-A1 | CYTOTOXIC AGENTS | PHEON THERAPEUTICS LTD (GB) | 2021-04-15 | — | — | US | disclosed |
| EP-3578563-B1 | GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS | GERON CORP (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3801630-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2021-04-14 | — | — | EP | disclosed |
| US-20210093731-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2021-04-01 | — | — | US | disclosed |
| EP-3544636-B1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | ADC THERAPEUTICS SA (CH) | 2021-03-31 | — | — | EP | disclosed |
| US-10960570-B2 | Additives for lignocellulosic composites | HEXION INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20210079023-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF AS ANTITUMOUR AGENTS | MEDIMMUNE LIMITED (GB) | 2021-03-18 | — | — | US | disclosed |
| US-20210079020-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2021-03-18 | — | — | US | disclosed |
| EP-3525830-B1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LTD (GB) | 2021-03-10 | — | — | EP | disclosed |
| CN-112391092-A | Acrylic resin coating | 上海婉静纺织科技有限公司 | 2021-02-23 | — | — | CN | disclosed |
| EP-2935268-B2 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LTD (GB) | 2021-02-17 | — | — | EP | disclosed |
| EP-3774699-A1 | RADIOLABELLED COMPOUND | Oxford University Innovation Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| EP-3774820-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF AS ANTITUMOUR AGENTS | MedImmune Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| CN-112239523-A | Acrylic resin and preparation method thereof | 宁波高新区巴艺新材料科技有限公司 | 2021-01-19 | — | — | CN | disclosed |
| US-20200405873-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2020-12-31 | — | — | US | disclosed |
| US-20200405880-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | BLUE OWL OPPORTUNISTIC MASTER FUND I, L.P. (FORMERLY KNOWN AS OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P.) | 2020-12-31 | — | — | US | disclosed |
| US-20200405878-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2020-12-31 | — | — | US | disclosed |
| US-20200399365-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2020-12-24 | — | — | US | disclosed |
| WO-2020245283-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | ADC THERAPEUTICS SA (CH) | 2020-12-10 | — | — | WO | disclosed |
| US-20200345861-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | BLUE OWL OPPORTUNISTIC MASTER FUND I, L.P. (FORMERLY KNOWN AS OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P.) | 2020-11-05 | — | — | US | disclosed |
| US-20200338209-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2020-10-29 | — | — | US | disclosed |
| EP-3198072-B1 | NON-FLUORINATED URETHANE BASED COATINGS | CHEMOURS CO FC LLC (US) | 2020-10-28 | — | — | EP | disclosed |
| US-10799596-B2 | Pyrrolobenzodiazepine-antibody conjugates | ADC THERAPEUTICS S.A. (CH) | 2020-10-13 | — | — | US | disclosed |
| US-10799595-B2 | Pyrrolobenzodiazepine conjugates | MEDIMMUNE LIMITED (GB) | 2020-10-13 | — | — | US | disclosed |
| US-20200306385-A1 | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2020-10-01 | — | — | US | disclosed |
| EP-3356474-B1 | COATINGS INCORPORATING HYDROPHOBIC COMPOUNDS | CHEMOURS CO FC LLC (US) | 2020-09-30 | — | — | EP | disclosed |
| WO-2020187721-A1 | AZETIDOBENZODIAZEPINE DIMERS AND CONJUGATES COMPRISING THEM FOR USE IN THE TREATMENT OF CANCER | MEDIMMUNE LIMITED (GB) | 2020-09-24 | — | — | WO | disclosed |
| EP-3710066-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | Medimmune Limited (GB) | 2020-09-23 | — | — | EP | disclosed |
| US-10780181-B2 | Pyrrolobenzodiazepine-antibody conjugates | MEDIMMUNE LIMITED (GB) | 2020-09-22 | — | — | US | disclosed |
| US-10780096-B2 | Pyrrolobenzodiazepine-antibody conjugates | ADC THERAPEUTICS SA (CH) | 2020-09-22 | — | — | US | disclosed |
| US-20200289660-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2020-09-17 | — | — | US | disclosed |
| US-20200283461-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2020-09-10 | — | — | US | disclosed |
| US-10751346-B2 | Pyrrolobenzodiazepine—anti-PSMA antibody conjugates | MEDIMMUNE LIMITED (GB) | 2020-08-25 | — | — | US | disclosed |
| US-10736903-B2 | Pyrrolobenzodiazepine-anti-PSMA antibody conjugates | MEDIMMUNE LIMITED (GB) | 2020-08-11 | — | — | US | disclosed |
| WO-2020157491-A1 | G-A CROSSLINKING CYTOTOXIC AGENTS | FEMTOGENIX LIMITED (GB) | 2020-08-06 | — | — | WO | disclosed |
| US-20200247823-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2020-08-06 | — | — | US | disclosed |
| US-10729793-B2 | Method for imaging arthritis | GUY'S AND ST. THOMAS' HOSPITAL NHS FOUNDATION TRUST (GB) | 2020-08-04 | — | — | US | disclosed |
| US-10722594-B2 | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates | ADC THERAPEUTICS S.A. (CH) | 2020-07-28 | — | — | US | disclosed |
| EP-3679045-A1 | CYTOTOXIC AGENTS | Femtogenix Limited (GB) | 2020-07-15 | — | — | EP | disclosed |
| US-10695433-B2 | Pyrrolobenzodiazepine-antibody conjugates | MEDIMMUNE LIMITED (GB) | 2020-06-30 | — | — | US | disclosed |
| EP-3668874-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | Medimmune Limited (GB) | 2020-06-24 | — | — | EP | disclosed |
| US-20200147235-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2020-05-14 | — | — | US | disclosed |
| US-10640563-B2 | Anti-B7-H3 antibodies and antibody drug conjugates | ABBVIE INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20200129637-A1 | COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2020-04-30 | — | — | US | disclosed |
| US-20200121803-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2020-04-23 | — | — | US | disclosed |
| WO-2020079229-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2020-04-23 | — | — | WO | disclosed |
| WO-2020079239-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2020-04-23 | — | — | WO | disclosed |
| US-20200115390-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2020-04-16 | — | — | US | disclosed |
| EP-3630779-A1 | ANTIBIOTIC RESISTANCE BREAKERS | Kings College London (GB) | 2020-04-08 | — | — | EP | disclosed |
| EP-2182936-B1 | SUBSTRATE REDUCTION THERAPY | THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIV OF OXFORD (GB) | 2020-04-01 | — | — | EP | disclosed |
| WO-2020053596-A1 | FLUORINATION METHOD | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2020-03-19 | — | — | WO | disclosed |
| US-10576164-B2 | Pyrrolobenzodiazepines and conjugates thereof | MEDIMMUNE LIMITED (GB) | 2020-03-03 | — | — | US | disclosed |
| EP-3612537-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | Medimmune Limited (GB) | 2020-02-26 | — | — | EP | disclosed |
| EP-3612234-A1 | COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE | ADC Therapeutics SA (CH) | 2020-02-26 | — | — | EP | disclosed |
| US-20200054761-A1 | METHODS AND COMPOSITION FOR INHIBITING TUMOR GROWTH AND ENHANCING IMMUNE RESPONSES TO TUMORS | THOMAS JEFFERSON UNIVERSITY (US) | 2020-02-20 | — | — | US | disclosed |
| US-10561739-B2 | Targeted pyrrolobenzodiazapine conjugates | SEATTLE GENETICS INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562926-B2 | Guanine analogs as telomerase substrates and telomere length affectors | GERON CORPORATION (US) | 2020-02-18 | — | — | US | disclosed |
| US-10544223-B2 | Combination therapy with an anti-axl antibody-drug conjugate | ADC THERAPEUTICS SA (CH) | 2020-01-28 | — | — | US | disclosed |
| WO-2020016573-A1 | MOLECULAR HOPPER | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2020-01-23 | — | — | WO | disclosed |
| US-10514383-B2 | Diagnosis and treatment of neonatal encephalopathy | INFANDX AG (DE) | 2019-12-24 | — | — | US | disclosed |
| WO-2019224340-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2019-11-28 | — | — | WO | disclosed |
| CN-110461366-A | Pyrrolobenzodiazepine-antibody conjugates | MEDIMMUNE LTD | 2019-11-15 | — | — | CN | disclosed |
| US-20190336614-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SEAGEN INC. | 2019-11-07 | — | — | US | disclosed |
| US-10449192-B2 | Phthalazinone derivatives | KUDO PHARMACEUTICALS LIMITED (GB) | 2019-10-22 | — | — | US | disclosed |
| WO-2019197602-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF AS ANTITUMOUR AGENTS | MEDIMMUNE LIMITED (GB) | 2019-10-17 | — | — | WO | disclosed |
| WO-2019186135-A1 | RADIOLABELLED COMPOUND | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-10-03 | — | — | WO | disclosed |
| EP-3544636-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | ADC Therapeutics SA (CH) | 2019-10-02 | — | — | EP | disclosed |
| CN-110300601-A | Pyrrolobenzodiazepines *-antibody conjugates | ADC治疗有限公司 | 2019-10-01 | — | — | CN | disclosed |
| US-10420777-B2 | Pyrrolobenzodiazepines and conjugates thereof | MEDIMMUNE LIMITED (GB) | 2019-09-24 | — | — | US | disclosed |
| CN-110267686-A | Pyrrolobenzodiazepines *-antibody conjugates | ADC治疗有限公司 | 2019-09-20 | — | — | CN | disclosed |
| US-20190282705-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2019-09-19 | — | — | US | disclosed |
| EP-3535336-A1 | COATINGS INCORPORATING NON-FLUORINATED CLEANABILITY ADDITIVES | The Chemours Company FC, LLC (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-3535331-A1 | NON-FLUORINATED COATING AND FINISH AGENTS | The Chemours Company FC, LLC (US) | 2019-09-11 | — | — | EP | disclosed |
| US-20190270219-A1 | ADDITIVES FOR LIGNOCELLULOSIC COMPOSITES | HEXION INC. | 2019-09-05 | — | — | US | disclosed |
| US-10399970-B2 | Pyrridinobenzodiazepine and benzopyrridodiazecine compounds | FEMTOGENIX LIMITED (GB) | 2019-09-03 | — | — | US | disclosed |
| US-10392393-B2 | Pyrrolobenzodiazepines | MEDIMMUNE LIMITED (GB) | 2019-08-27 | — | — | US | disclosed |
| US-20190256739-A1 | NON-FLUORINATED COATING AND FINISH AGENTS | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2019-08-22 | — | — | US | disclosed |
| US-20190256729-A1 | COATINGS INCORPORATING NON-FLUORINATED CLEANABILITY ADDITIVES | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2019-08-22 | — | — | US | disclosed |
| EP-3525830-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | Medimmune Limited (GB) | 2019-08-21 | — | — | EP | disclosed |
| EP-3191490-B1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LTD (GB) | 2019-08-07 | — | — | EP | disclosed |
| US-20190218291-A1 | COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2019-07-18 | — | — | US | disclosed |
| US-10328084-B2 | Pyrrolobenzodiazepines and targeted conjugates | SEATTLE GENETICS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-10329352-B2 | Pyrrolobenzodiazepines and targeted conjugates | SEATTLE GENETICS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| CN-105209077-B | Pyrrolobenzodiazepines and conjugates thereof | 麦迪穆有限责任公司 | 2019-06-11 | — | — | CN | disclosed |
| US-10308898-B2 | Method of imparting water repellency with non-fluorinated laundry treatment compositions | THE CHEMOURS COMPANY FC, LLC (US) | 2019-06-04 | — | — | US | disclosed |
| CN-109843335-A | Pyrrolobenzodiazepines Zhuo conjugate | 麦迪穆有限责任公司 | 2019-06-04 | — | — | CN | disclosed |
| US-20190144443-A1 | ASYMMETRIC CONJUGATE COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2019-05-16 | — | — | US | disclosed |
| EP-2794624-B1 | GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS | GERON CORP (US) | 2019-05-15 | — | — | EP | disclosed |
| US-10287220-B2 | Fluorination method | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-05-14 | — | — | US | disclosed |
| US-20190134216-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2019-05-09 | — | — | US | disclosed |
| EP-3197963-B1 | NON-FLUORINATED MONOMERS AND POLYMERS FOR SURFACE EFFECT COMPOSITIONS | CHEMOURS CO FC LLC (US) | 2019-05-01 | — | — | EP | disclosed |
| US-20190119433-A1 | SULFONATED FLUORINATED, NON-FLUORINATED OR PARTIALLY FLUORINATED URETHANES | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2019-04-25 | — | — | US | disclosed |
| EP-2968594-B1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LTD (GB) | 2019-04-24 | — | — | EP | disclosed |
| EP-3468599-A2 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3469000-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3468598-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3468596-A2 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3468993-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| US-20190106447-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2019-04-11 | — | — | US | disclosed |
| CN-109562169-A | anti-CD 98 antibodies and antibody drug conjugates | 艾伯维公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-109562168-A | anti-CD 98 antibodies and antibody drug conjugates | 艾伯维公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-109562170-A | anti-CD 98 antibodies and antibody drug conjugates | 艾伯维公司 | 2019-04-02 | — | — | CN | disclosed |
| US-10246608-B2 | Non-fluorinated urethane based coatings | THE CHEMOURS COMPANY FC, LLC (US) | 2019-04-02 | — | — | US | disclosed |
| EP-3458479-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| US-20190085017-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | CLINIGEN GROUP PLC (GB) | 2019-03-21 | — | — | US | disclosed |
| EP-3455225-A1 | ASYMMETRIC CONJUGATE COMPOUNDS | Femtogenix Limited (GB) | 2019-03-20 | — | — | EP | disclosed |
| EP-2902402-B1 | WATER-SOLUBLE PHOTOCHROMIC MOLECULE | RIKKYO EDUCATIONAL CORP (JP) | 2019-03-13 | — | — | EP | disclosed |
| WO-2019043417-A1 | CYTOTOXIC AGENTS | FEMTOGENIX LIMITED (GB) | 2019-03-07 | — | — | WO | disclosed |
| US-20190070305-A1 | BENZODIAZEPINES AND CONJUGATES THEREOF | IMMUNOGEN, INC. | 2019-03-07 | — | — | US | disclosed |
| WO-2019034764-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2019-02-21 | — | — | WO | disclosed |
| US-20190055254-A1 | PYRROLOBENZODIAZEPINES | MEDIMMUNE LIMITED (GB) | 2019-02-21 | — | — | US | disclosed |
| US-10208155-B2 | Sulfonated fluorinated, non-fluorinated or partially fluorinated urethanes | THE CHEMOURS COMPANY FC, LLC (US) | 2019-02-19 | — | — | US | disclosed |
| US-20190040270-A1 | COATINGS INCORPORATING HYDROPHOBIC COMPOUNDS | THE CHEMOURS COMPANY FC, LLC (US) | 2019-02-07 | — | — | US | disclosed |
| US-10188746-B2 | Pyrrolobenzodiazepines and conjugates thereof | MEDIMMUNE LIMITED (GB) | 2019-01-29 | — | — | US | disclosed |
| US-20190015524-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | MEDIMMUNE LIMITED (GB) | 2019-01-17 | — | — | US | disclosed |
| CN-106687472-B | Pyrrolobenzodiazepines Zhuo and its conjugate | 麦迪穆有限责任公司 | 2019-01-08 | — | — | CN | disclosed |
| CN-109071502-A | Pyrrolobenzodiazepines * | 麦迪穆有限责任公司 | 2018-12-21 | — | — | CN | disclosed |
| US-20180362644-A1 | PYRROLOBENZODIAZEPINES AND ANTIBODY DISULFIDE CONJUGATES THEREOF | GENENTECH INC (US) | 2018-12-20 | — | — | US | disclosed |
| WO-2018220365-A1 | ANTIBIOTIC RESISTANCE BREAKERS | KING'S COLLEGE LONDON (GB) | 2018-12-06 | — | — | WO | disclosed |
| EP-3408267-A1 | PYRROLOBENZODIAZEPINES | Medimmune Limited (GB) | 2018-12-05 | — | — | EP | disclosed |
| US-10138594-B2 | Partially fluorinated urethane based coatings | THE CHEMOURS COMPANY FC, LLC (US) | 2018-11-27 | — | — | US | disclosed |
| US-20180320309-A1 | CARPET WITH HYDROPHOBIC SURFACE FINISH | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2018-11-08 | — | — | US | disclosed |
| US-20180320005-A1 | HYDROPHOBIC EXTENDERS IN NON-FLUORINATED SURFACE EFFECT COATINGS | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2018-11-08 | — | — | US | disclosed |
| WO-2018192944-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2018-10-25 | — | — | WO | disclosed |
| WO-2018193102-A1 | COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE | ADC THERAPEUTICS SA (CH) | 2018-10-25 | — | — | WO | disclosed |
| US-20180303953-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | ADC THERAPEUTICS S.A. (CH) | 2018-10-25 | — | — | US | disclosed |
| EP-3388435-A1 | PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES | Seattle Genetics, Inc. (US) | 2018-10-17 | — | — | EP | disclosed |
| US-10098968-B2 | Anti-EGFR antibodies and antibody drug conjugates | ABBVIE INC. (US) | 2018-10-16 | — | — | US | disclosed |
| US-20180282514-A1 | SOLID POLYMERIC ARTICLES HAVING HYDROPHOBIC COMPOUNDS INTERMIXED THEREIN | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2018-10-04 | — | — | US | disclosed |
| US-20180282571-A1 | HYDROPHOBIC COMPOUND EXTENDERS IN SURFACE EFFECT COATINGS | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2018-10-04 | — | — | US | disclosed |
| US-20180273774-A1 | HYDROPHOBIC EXTENDERS IN FLUORINATED SURFACE EFFECT COATINGS | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2018-09-27 | — | — | US | disclosed |
| US-20180250417-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2018-09-06 | — | — | US | disclosed |
| WO-2018156725-A1 | METHODS AND COMPOSITIONS FOR INHIBITING TUMOR GROWTH AND ENHANCING IMMUNE RESPONSES TO TUMORS | THOMAS JEFFERSON UNIVERSITY (US) | 2018-08-30 | — | — | WO | disclosed |
| EP-2751120-B1 | PYRROLOBENZODIAZEPINES AS UNSYMMETRICAL DIMERIC PBD COMPOUNDS FOR INCLUSION IN TARGETED CONJUGATES | MEDIMMUNE LTD (GB) | 2018-08-22 | — | — | EP | disclosed |
| WO-2018146199-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | ADC THERAPEUTICS SA (CH) | 2018-08-16 | — | — | WO | disclosed |
| WO-2018146189-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | ADC THERAPEUTICS SA (CH) | 2018-08-16 | — | — | WO | disclosed |
| WO-2018146188-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | MEDIMMUNE LIMITED (GB) | 2018-08-16 | — | — | WO | disclosed |
| EP-3356474-A1 | COATINGS INCORPORATING HYDROPHOBIC COMPOUNDS | The Chemours Company FC, LLC (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3356475-A1 | HYDROPHOBIC COMPOUND EXTENDERS IN SURFACE EFFECT COATINGS | The Chemours Company FC, LLC (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3356477-A1 | HYDROPHOBIC EXTENDERS IN FLUORINATED SURFACE EFFECT COATINGS | The Chemours Company FC, LLC (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3356460-A1 | SOLID POLYMERIC ARTICLES HAVING HYDROPHOBIC COMPOUNDS INTERMIXED THEREIN | The Chemours Company FC, LLC (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3356476-A1 | HYDROPHOBIC EXTENDERS IN NON-FLUORINATED SURFACE EFFECT COATINGS | The Chemours Company FC, LLC (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3356594-A1 | CARPET WITH HYDROPHOBIC SURFACE FINISH | The Chemours Company FC, LLC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-10035814-B2 | Guanine analogs as telomerase substrates and telomere length affectors | GERON CORPORATION (US) | 2018-07-31 | — | — | US | disclosed |
| US-10034884-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2018-07-31 | — | — | US | disclosed |
| EP-2755642-B1 | PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES | SEATTLE GENETICS INC (US) | 2018-07-18 | — | — | EP | disclosed |
| EP-2968585-B1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LTD (GB) | 2018-07-18 | — | — | EP | disclosed |
| US-20180193480-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | MEDIMMUNE LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-10017580-B2 | Humanized anti-Tn-MUC1 antibodies and their conjugates | ADC Therpeutics S.A. (CH) | 2018-07-10 | — | — | US | disclosed |
| US-20180185522-A1 | CONTRAST AGENT FOR IMAGING HYPOXIA | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2018-07-05 | — | — | US | disclosed |
| US-20180185523-A1 | METHOD FOR IMAGING ARTHRITIS | GUY'S AND ST. THOMAS' HOSPITAL NHS FOUNDATION TRUST (GB) | 2018-07-05 | — | — | US | disclosed |
| US-20180185363-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2018-07-05 | — | — | US | disclosed |
| US-10011617-B2 | Isocyanate derived organosilanes | THE CHEMOURS COMPANY FC, LLC (US) | 2018-07-03 | — | — | US | disclosed |
| EP-2906249-B1 | SYNTHESIS AND INTERMEDIATES OF PYRROLOBENZODIAZEPINE DERIVATIVES FOR CONJUGATION | MEDIMMUNE LTD (GB) | 2018-06-27 | — | — | EP | disclosed |
| US-20180169259-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180169258-A1 | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2018-06-21 | — | — | US | disclosed |
| US-9999625-B2 | Pyrrolobenzodiazepine compounds | FEMTOGENIX LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-20180162855-A1 | PDD AND BPD COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2018-06-14 | — | — | US | disclosed |
| EP-3328497-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | ADC Therapeutics SA (CH) | 2018-06-06 | — | — | EP | disclosed |
| US-20180134717-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
| US-20180125796-A1 | TREATMENT OF MYCOBACTERIAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-05-10 | — | — | US | disclosed |
| US-20180127505-A1 | HUMANIZED ANTI-AXL ANTIBODIES AND THEIR CONJUGATES | ADC THERAPEUTICS SA (CH) | 2018-05-10 | — | — | US | disclosed |
| US-20180125997-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2018-05-10 | — | — | US | disclosed |
| US-20180125999-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180125994-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | MEDIMMUNE LIMITED (GB) | 2018-05-10 | — | — | US | disclosed |
| US-20180117172-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | VAN BERKEL PATRICIUS HENDRIKUS CORNELIS (CH) | 2018-05-03 | — | — | US | disclosed |
| EP-3313453-A1 | METHOD FOR IMAGING ARTHRITIS | Guy's And St Thomas' Nhs Foundation Trust (GB) | 2018-05-02 | — | — | EP | disclosed |
| US-9957661-B2 | Polyurethanes derived from non-fluorinated or partially fluorinated polymers | THE CHEMOURS COMPANY FC, LLC (US) | 2018-05-01 | — | — | US | disclosed |
| EP-2751076-B1 | SYNTHESIS METHOD AND INTERMEDIATES USEFUL IN THE PREPARATION OF PYRROLOBENZODIAZEPINES | MEDIMMUNE LTD (GB) | 2018-04-25 | — | — | EP | disclosed |
| WO-2018069490-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2018-04-19 | — | — | WO | disclosed |
| EP-3309162-A1 | TARGETED CONJUGATES OF PYRROLOBENZODIAZEPINES | Seattle Genetics, Inc. (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-3307743-A1 | PDD AND BPD COMPOUNDS | Femtogenix Limited (GB) | 2018-04-18 | — | — | EP | disclosed |
| US-20180099055-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | MEDIMMUNE LIMITED (GB) | 2018-04-12 | — | — | US | disclosed |
| US-9938431-B2 | Use of non-fluorinated or partially fluorinated urethanes in coatings | THE CHEMOURS COMPANY FC, LLC (US) | 2018-04-10 | — | — | US | disclosed |
| US-20180092986-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | MEDIMMUNE LIMITED (GB) | 2018-04-05 | — | — | US | disclosed |
| US-20180092985-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | MEDIMMUNE LIMITED (GB) | 2018-04-05 | — | — | US | disclosed |
| US-9931414-B2 | Pyrrolobenzodiazepine-antibody conjugates | MEDIMMUNE LIMITED (GB) | 2018-04-03 | — | — | US | disclosed |
| US-9931415-B2 | Pyrrolobenzodiazepine-antibody conjugates | MEDIMMUNE LIMITED (GB) | 2018-04-03 | — | — | US | disclosed |
| US-20180086828-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | MEDIMMUNE LIMITED (GB) | 2018-03-29 | — | — | US | disclosed |
| EP-2422183-B1 | OXIDATION STATE SENSORS AND METHODS FOR TRANSITION METAL ALLOYS | ROLLS ROYCE PLC (GB) | 2018-03-21 | — | — | EP | disclosed |
| US-9919056-B2 | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates | ADC THERAPEUTICS S.A. (CH) | 2018-03-20 | — | — | US | disclosed |
| US-9915025-B2 | Non-fluorinated monomers and polymers for surface effect compositions | THE CHEMOURS COMPANY FC, LLC (US) | 2018-03-13 | — | — | US | disclosed |
| EP-3283116-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | ADC Therapeutics SA (CH) | 2018-02-21 | — | — | EP | disclosed |
| EP-3283119-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | ADC Therapeutics SA (CH) | 2018-02-21 | — | — | EP | disclosed |
| EP-3283121-A1 | HUMANIZED ANTI-AXL ANTIBODIES AND THEIR CONJUGATES | ADC Therapeutics SA (CH) | 2018-02-21 | — | — | EP | disclosed |
| EP-3283117-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | ADC Therapeutics SA (CH) | 2018-02-21 | — | — | EP | disclosed |
| EP-3283123-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | ADC Therapeutics SA (CH) | 2018-02-21 | — | — | EP | disclosed |
| EP-3283120-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | Medimmune Limited (GB) | 2018-02-21 | — | — | EP | disclosed |
| EP-3283118-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | ADC Therapeutics SA (CH) | 2018-02-21 | — | — | EP | disclosed |
| EP-3283122-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | ADC Therapeutics SA (CH) | 2018-02-21 | — | — | EP | disclosed |
| CN-104684914-B | Pyrrolobenzodiazepines are tall and erect | 麦迪穆有限责任公司 | 2017-12-15 | — | — | CN | disclosed |
| US-20170355769-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2017-12-14 | — | — | US | disclosed |
| WO-2017214462-A2 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017214456-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017214335-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017214458-A2 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20170340752-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2017-11-30 | — | — | US | disclosed |
| US-9827330-B2 | Anti-EGFR antibodies and antibody drug conjugates | ABBVIE INC. (US) | 2017-11-28 | — | — | US | disclosed |
| EP-2935268-B1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LTD (GB) | 2017-11-22 | — | — | EP | disclosed |
| US-9821074-B2 | Pyrrolobenzodiazepines and conjugates thereof | GENENTECH, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| WO-2017194960-A1 | ASYMMETRIC CONJUGATE COMPOUNDS | FEMTOGENIX LIMITED (GB) | 2017-11-16 | — | — | WO | disclosed |
| EP-3235820-A1 | PYRROLOBENZODIAZEPINES AND ANTIBODY DISULFIDE CONJUGATES THEREOF | Genentech, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170298137-A1 | PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES | SEAGEN INC. | 2017-10-19 | — | — | US | disclosed |
| US-20170290924-A1 | PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES | SEAGEN INC. | 2017-10-12 | — | — | US | disclosed |
| US-20170290920-A1 | ANTI-CD22 ANTIBODIES AND IMMUNOCONJUGATES | MEDIMMUNE LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| US-20170281637-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| EP-3223854-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | ADC Therapeutics SA (CH) | 2017-10-04 | — | — | EP | disclosed |
| US-20170274091-A1 | BENZODIAZEPINES AND CONJUGATES THEREOF | IMMUNOGEN, INC. | 2017-09-28 | — | — | US | disclosed |
| US-20170267778-A1 | HUMANIZED ANTI-TN-MUC1 ANTIBODIES AND THEIR CONJUGATES | MEDIMMUNE LIMITED (GB) | 2017-09-21 | — | — | US | disclosed |
| US-20170268165-A1 | POLYURETHANES DERIVED FROM NON-FLUORINATED OR PARTIALLY FLUORINATED POLYMERS | THE CHEMOURS COMPANY FC, LLC | 2017-09-21 | — | — | US | disclosed |
| US-20170258934-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2017-09-14 | — | — | US | disclosed |
| CN-107148285-A | Pyrrolobenzodiazepines * antibody conjugates | ADC治疗股份有限公司 | 2017-09-08 | — | — | CN | disclosed |
| US-9745303-B2 | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation | MEDIMMUNE LIMITED (GB) | 2017-08-29 | — | — | US | disclosed |
| US-20170239365-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2017-08-24 | — | — | US | disclosed |
| EP-2869850-B1 | IMMUNOCONJUGATES COMPRISING ANTI-CD79B ANTIBODIES | GENENTECH INC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-9738675-B2 | Water-soluble photochromic compound | RIKKYO EDUCATIONAL CORPORATION (JP) | 2017-08-22 | — | — | US | disclosed |
| CN-107073136-A | Pyrrolobenzodiazepines Zhuo and its antibody disulphide conjugate | 健泰科生物技术公司 | 2017-08-18 | — | — | CN | disclosed |
| US-20170233419-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2017-08-17 | — | — | US | disclosed |
| US-9732084-B2 | Pyrrolobenzodiazepines used to treat proliferative diseases | MEDIMMUNE LIMITED (GB) | 2017-08-15 | — | — | US | disclosed |
| US-20170226124-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-08-10 | — | — | US | disclosed |
| CN-107019804-A | Target the tall and erect conjugate of Pyrrolobenzodiazepines | 西雅图基因公司 | 2017-08-08 | — | — | CN | disclosed |
| WO-2017129652-A1 | PYRROLOBENZODIAZEPINES | MEDIMMUNE LIMITED (GB) | 2017-08-03 | — | — | WO | disclosed |
| EP-3198072-A1 | NON-FLUORINATED URETHANE BASED COATINGS | The Chemours Company FC, LLC (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-3197932-A1 | NON-FLUORINATED AND PARTIALLY FLUORINATED POLYMERS | The Chemours Company FC, LLC (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-3197866-A1 | PARTIALLY FLUORINATED URETHANE BASED COATINGS | The Chemours Company FC, LLC (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-3197931-A1 | USE OF NON-FLUORINATED OR PARTIALLY FLUORINATED URETHANES IN COATINGS | The Chemours Company FC, LLC (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-3197865-A1 | SULFONATED FLUORINATED, NON-FLUORINATED OR PARTIALLY FLUORINATED URETHANES | The Chemours Company FC, LLC (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-3197903-A1 | ISOCYANATE DERIVED ORGANOSILANES | The Chemours Company FC, LLC (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-3197963-A1 | NON-FLUORINATED MONOMERS AND POLYMERS FOR SURFACE EFFECT COMPOSITIONS | The Chemours Company FC, LLC (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-3197927-A1 | POLYURETHANES DERIVED FROM NON-FLUORINATED OR PARTIALLY FLUORINATED POLYMERS | The Chemours Company FC, LLC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-9717736-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-08-01 | — | — | US | disclosed |
| EP-3194400-A1 | PYRROLOBENZODIAZEPINES AND ANTIBODY DISULFIDE CONJUGATES THEREOF | Genentech, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-3193940-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | Medimmune Limited (GB) | 2017-07-26 | — | — | EP | disclosed |
| US-9713647-B2 | Pyrrolobenzodiazepines and targeted conjugates | SEATTLE GENETICS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| EP-3191490-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | Medimmune Limited (GB) | 2017-07-19 | — | — | EP | disclosed |
| EP-1789430-B1 | DERIVATES OF AVERMECTIN,AVERMECTIN MONOSACCHARIDE AND AVERMECTIN AGLYCONE | MERIAL LTD (US) | 2017-07-19 | — | — | EP | disclosed |
| US-9709571-B2 | Method of drug design | VAST BIOSCIENCE PTY LIMITED (AU) | 2017-07-18 | — | — | US | disclosed |
| US-9707301-B2 | Pyrrolobenzodiazepines and targeted conjugates | SEATTLE GENETICS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9702081-B2 | Polyurethanes derived from non-fluorinated or partially fluorinated polymers | THE CHEMOURS COMPANY FC, LLC (US) | 2017-07-11 | — | — | US | disclosed |
| US-20170143846-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SPIROGEN LIMITED (GB) | 2017-05-25 | — | — | US | disclosed |
| US-20170145046-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | CLINIGEN GROUP PLC (GB) | 2017-05-25 | — | — | US | disclosed |
| US-20170137341-A1 | FLUORINATION METHOD | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-05-18 | — | — | US | disclosed |
| CN-106687472-A | Pyrrolobenzodiazepines and conjugates thereof | 麦迪穆有限责任公司 | 2017-05-17 | — | — | CN | disclosed |
| CN-106687141-A | Pyrrolobenzodiazepines and conjugates thereof | 麦迪穆有限责任公司 | 2017-05-17 | — | — | CN | disclosed |
| US-9649390-B2 | Pyrrolobenzodiazepines and conjugates thereof | MEDIMMUNE LIMITED (GB) | 2017-05-16 | — | — | US | disclosed |
| EP-3164418-A1 | HUMANIZED ANTI-TN-MUC1 ANTIBODIES AND THEIR CONJUGATES | Cancer Research Technology Ltd (GB) | 2017-05-10 | — | — | EP | disclosed |
| EP-2751111-B1 | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases | MEDIMMUNE LTD (GB) | 2017-04-26 | — | — | EP | disclosed |
| US-20170107235-A1 | PYRROLOBENZODIAZEPINE COMPOUNDS FOR TREATING LYMPHOMA | ADC PRODUCTS (UK) LIMITED (GB) | 2017-04-20 | — | — | US | disclosed |
| EP-2751110-B1 | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative and autoimmune diseases | MEDIMMUNE LTD (GB) | 2017-04-19 | — | — | EP | disclosed |
| US-9624227-B2 | Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases | MEDIMMUNE LIMITED (GB) | 2017-04-18 | — | — | US | disclosed |
| EP-3148548-A1 | PYRROLOBENZODIAZEPINE COMPOUNDS FOR TREATING LYMPHOMA | ADC Products (UK) Limited (GB) | 2017-04-05 | — | — | EP | disclosed |
| EP-2558445-B1 | INTERMEDIATES USEFUL FOR THE SYNTHESIS OF PYRROLOBENZODIAZEPINES | MEDIMMUNE LTD (GB) | 2017-03-22 | — | — | EP | disclosed |
| US-20170072065-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2017-03-16 | — | — | US | disclosed |
| US-9592240-B2 | Targeted pyrrolobenzodiazapine conjugates | SEATTLE GENETICS INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593137-B2 | Guanine analogs as telomerase substrates and telomere length affectors | GERON CORPORATION (US) | 2017-03-14 | — | — | US | disclosed |
| EP-2855482-B1 | PYRROLOBENZODIAZEPINES | MEDIMMUNE LTD (GB) | 2017-03-01 | — | — | EP | disclosed |
| EP-2789622-B1 | Pyrrolobenzodiazepines used to treat proliferative diseases | MEDIMMUNE LTD (GB) | 2017-03-01 | — | — | EP | disclosed |
| US-20170050971-A1 | PYRROLOBENZODIAZEPINE COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2017-02-23 | — | — | US | disclosed |
| US-9566276-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-02-14 | — | — | US | disclosed |
| US-9567340-B2 | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases | MEDIMMUNE LIMITED (GB) | 2017-02-14 | — | — | US | disclosed |
| WO-2017020972-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | VAN BERKEL, Patricius Hendrikus Cornelis (CH) | 2017-02-09 | — | — | WO | disclosed |
| EP-3126006-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| US-9562049-B2 | Pyrrolobenzodiazepines and conjugates thereof | MEDIMMUNE LIMITED (GB) | 2017-02-07 | — | — | US | disclosed |
| EP-2057156-B1 | 2-METHYLMORPHOLINE PYRIDO-,PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | KUDOS PHARM LTD (GB) | 2017-02-01 | — | — | EP | disclosed |
| US-9555125-B2 | Benzodiazepines and conjugates thereof | IMMUNOGEN, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| EP-3119737-A1 | FLUORINATION METHOD | Oxford University Innovation Limited (GB) | 2017-01-25 | — | — | EP | disclosed |
| WO-2016207636-A1 | METHOD FOR IMAGING ARTHRITIS | GUY'S AND ST THOMAS' HOSPITAL NHS FOUNDATION TRUST (GB) | 2016-12-29 | — | — | WO | disclosed |
| US-9526798-B2 | Pyrrolobenzodiazepines and targeted conjugates | SEATTLE GENETICS, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| WO-2016198869-A1 | PDD AND BPD COMPOUNDS | FEMTOGENIX LIMITED (GB) | 2016-12-15 | — | — | WO | disclosed |
| US-9493568-B2 | Anti-EGFR antibodies and antibody drug conjugates | ABBVIE INC. (US) | 2016-11-15 | — | — | US | disclosed |
| WO-2016166300-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | VAN BERKEL PATRICIUS HENDRIKUS CORNELIS (CH) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016166302-A1 | HUMANIZED ANTI-AXL ANTIBODIES AND THEIR CONJUGATES | VAN BERKEL PATRICIUS HENDRIKUS CORNELIS (CH) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016166341-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | VAN BERKEL PATRICIUS HENDRIKUS CORNELIS (CH) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016166305-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016166304-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | VAN BERKEL PATRICIUS HENDRIKUS CORNELIS (CH) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016166297-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | VAN BERKEL PATRICIUS HENDRIKUS CORNELIS (CH) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016166301-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | VAN BERKEL PATRICIUS HENDRIKUS CORNELIS (CH) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016166298-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | VAN BERKEL PATRICIUS HENDRIKUS CORNELIS (CH) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016166307-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | VAN BERKEL PATRICIUS HENDRIKUS CORNELIS (CH) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016166299-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | VAN BERKEL PATRICIUS HENDRIKUS CORNELIS (CH) | 2016-10-20 | — | — | WO | disclosed |
| US-9464141-B2 | Anti-ETBR antibodies and immunoconjugates | GENENTECH, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160289239-A1 | PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES | SEAGEN INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160287721-A1 | PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES | SEAGEN INC. | 2016-10-06 | — | — | US | disclosed |
| WO-2016151295-A1 | FLUORINATION PROCESS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2016-09-29 | — | — | WO | disclosed |
| US-9428541-B2 | Substrate reduction therapy | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-08-30 | — | — | US | disclosed |
| US-9399641-B2 | Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates | MEDIMMUNE LIMITED (GB) | 2016-07-26 | — | — | US | disclosed |
| US-9399073-B2 | Pyrrolobenzodiazepines | SEATTLE GENETICS, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| WO-2016110702-A1 | TREATMENT OF MYCOBACTERIAL INFECTION | ISIS INNOVATION LIMITED (GB) | 2016-07-14 | — | — | WO | disclosed |
| US-9388187-B2 | Pyrrolobenzodiazepines | MEDIMMUNE LIMITED (GB) | 2016-07-12 | — | — | US | disclosed |
| US-9387259-B2 | Pyrrolobenzodiazepines and targeted conjugates | SEATTLE GENETICS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9387258-B2 | — | — | 2016-07-12 | — | — | US | disclosed |
| CN-102971329-B | Pyrrolobenzodiazepines for the treatment of proliferative diseases | 麦迪穆有限责任公司 | 2016-06-29 | — | — | CN | disclosed |
| US-9376440-B2 | Pyrrolobenzodiazepines as antiproliferative agents | MEDIMMUNE LIMITED (GB) | 2016-06-28 | — | — | US | disclosed |
| WO-2016092325-A1 | CONTRAST AGENT FOR IMAGING HYPOXIA | ISIS INNOVATION LIMITED (GB) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016083468-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | ADC THERAPEUTICS SA (CH) | 2016-06-02 | — | — | WO | disclosed |
| US-9356318-B2 | Gel polymer electrolyte composition | KURARAY CO., LTD. (JP) | 2016-05-31 | — | — | US | disclosed |
| US-20160144052-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN LIMITED (GB) | 2016-05-26 | — | — | US | disclosed |
| US-20160129013-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SEAGEN INC. | 2016-05-12 | — | — | US | disclosed |
| US-9321774-B2 | Pyrrolobenzodiazepines | MEDIMMUNE LIMITED (GB) | 2016-04-26 | — | — | US | disclosed |
| US-20160090392-A1 | ISOCYANATE DERIVED ORGANOSILANES | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2016-03-31 | — | — | US | disclosed |
| WO-2016048643-A1 | ISOCYANATE DERIVED ORGANOSILANES | THE CHEMOURS COMPANY FC, LLC (US) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016049293-A1 | USE OF NON-FLUORINATED OR PARTIALLY FLUORINATED URETHANES IN COATINGS | THE CHEMOURS COMPANY FC, LLC (US) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016048695-A1 | PARTIALLY FLUORINATED URETHANE BASED COATINGS | THE CHEMOURS COMPANY FC, LLC (US) | 2016-03-31 | — | — | WO | disclosed |
| US-20160090688-A1 | PARTIALLY FLUORINATED URETHANE BASED COATINGS | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2016-03-31 | — | — | US | disclosed |
| WO-2016049278-A1 | NON-FLUORINATED URETHANE BASED COATINGS | THE CHEMOURS COMPANY FC, LLC (US) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016048642-A1 | NON-FLUORINATED MONOMERS AND POLYMERS FOR SURFACE EFFECT COMPOSITIONS | THE CHEMOURS COMPANY FC, LLC (US) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016048696-A1 | POLYURETHANES DERIVED FROM NON-FLUORINATED OR PARTIALLY FLUORINATED POLYMERS | THE CHEMOURS COMPANY FC, LLC (US) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016049107-A1 | NON-FLUORINATED AND PARTIALLY FLUORINATED POLYMERS | THE CHEMOURS COMPANY FC, LLC (US) | 2016-03-31 | — | — | WO | disclosed |
| US-20160090438-A1 | SULFONATED FLUORINATED, NON-FLUORINATED OR PARTIALLY FLUORINATED URETHANES | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2016-03-31 | — | — | US | disclosed |
| US-20160090687-A1 | POLYURETHANES DERIVED FROM NON-FLUORINATED OR PARTIALLY FLUORINATED POLYMERS | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2016-03-31 | — | — | US | disclosed |
| WO-2016048684-A1 | METHOD OF IMPARTING WATER REPELLENCY WITH NON-FLUORINATED LAUNDRY TREATMENT COMPOSITIONS | THE CHEMOURS COMPANY FC, LLC (US) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016049282-A1 | SULFONATED FLUORINATED, NON-FLUORINATED OR PARTIALLY FLUORINATED URETHANES | THE CHEMOURS COMPANY FC, LLC (US) | 2016-03-31 | — | — | WO | disclosed |
| US-20160090508-A1 | NON-FLUORINATED URETHANE BASED COATINGS | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2016-03-31 | — | — | US | disclosed |
| US-20160090686-A1 | NON-FLUORINATED MONOMERS AND POLYMERS FOR SURFACE EFFECT COMPOSITIONS | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2016-03-31 | — | — | US | disclosed |
| US-20160090509-A1 | USE OF NON-FLUORINATED OR PARTIALLY FLUORINATED URETHANES IN COATINGS | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2016-03-31 | — | — | US | disclosed |
| US-20160090505-A1 | NON-FLUORINATED AND PARTIALLY FLUORINATED POLYMERS | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2016-03-31 | — | — | US | disclosed |
| US-20160090560-A1 | METHOD OF IMPARTING WATER REPELLENCY WITH NON-FLUORINATED LAUNDRY TREATMENT COMPOSITIONS | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2016-03-31 | — | — | US | disclosed |
| WO-2016044560-A1 | PYRROLOBENZODIAZEPINES AND ANTIBODY DISULFIDE CONJUGATES THEREOF | GENENTECH, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016038383-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2016-03-17 | — | — | WO | disclosed |
| WO-2016037644-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2016-03-17 | — | — | WO | disclosed |
| US-20160074527-A1 | PYRROLOBENZODIAZEPINES AND ANTIBODY DISULFIDE CONJUGATES THEREOF | GENENTECH, INC. | 2016-03-17 | — | — | US | disclosed |
| US-20160067258-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARM LTD (GB) | 2016-03-10 | — | — | US | disclosed |
| US-9273024-B2 | Synthesis of cyclic carbonates | UNIVERSITY OF YORK (GB) | 2016-03-01 | — | — | US | disclosed |
| US-20160056054-A1 | ETCHING METHOD, ETCHING LIQUID AND ETCHING LIQUID KIT TO BE USED IN SAID METHOD, AND SEMICONDUCTOR SUBSTRATE PRODUCT MANUFACTURING METHOD | FUJIFILM CORPORATION (JP) | 2016-02-25 | — | — | US | disclosed |
| US-9266894-B2 | — | — | 2016-02-23 | — | — | US | disclosed |
| EP-2675278-B1 | METHODS FOR SYNTHESIZING MOLYBDOPTERIN PRECURSOR Z DERIVATIVES | ALEXION PHARMA INTERNAT SÀRL (CH) | 2016-02-17 | — | — | EP | disclosed |
| US-9260382-B2 | Methods of reducing virulence in bacteria | UWM RESEARCH FOUNDATION (US) | 2016-02-16 | — | — | US | disclosed |
| US-20160031887-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN LIMITED (GB) | 2016-02-04 | — | — | US | disclosed |
| US-9242955-B2 | Synthesis of cyclic carbonates | UNIVERSITY OF YORK (GB) | 2016-01-26 | — | — | US | disclosed |
| US-9242013-B2 | Targeted pyrrolobenzodiazapine conjugates | SEATTLE GENETICS INC. (US) | 2016-01-26 | — | — | US | disclosed |
| EP-2968596-A2 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968585-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2016-01-20 | — | — | EP | disclosed |
| US-20160002144-A1 | HIGH REFRACTIVE INDEX POLYMER COMPOSITION FOR OPTHALMIC APPLICATIONS | CONTAMAC LTD (GB) | 2016-01-07 | — | — | US | disclosed |
| US-20160000781-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2016-01-07 | — | — | US | disclosed |
| CN-105209077-A | Pyrrolobenzodiazepines and conjugates thereof | MEDIMMUNE LTD | 2015-12-30 | — | — | CN | disclosed |
| US-9212245-B2 | High performance acrylamide adhesives | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212245-B2 | High performance acrylamide adhesives | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2015-12-15 | — | — | US | disclosed |
| WO-2015181559-A1 | PYRROLOBENZODIAZEPINE COMPOUNDS FOR TREATING LYMPHOMA | ADC PRODUCTS (UK) LIMITED (GB) | 2015-12-03 | — | — | WO | disclosed |
| US-20150344482-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-20150337042-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2015-11-26 | — | — | US | disclosed |
| EP-2524932-B1 | GEL POLYMER ELECTROLYTE COMPOSITION | KURARAY CO (JP) | 2015-11-25 | — | — | EP | disclosed |
| WO-2015170119-A1 | OXYGEN SENSOR COMPOUNDS | ISIS INNOVATION LIMITED (GB) | 2015-11-12 | — | — | WO | disclosed |
| US-20150315196-A1 | UNSYMMETRICAL PYRROLOBENZODIAZEPINES-DIMERS FOR USE IN THE TREATMENT OF PROLIFERATIVE AND AUTOIMMUNE DISEASES | MEDIMMUNE LIMITED (GB) | 2015-11-05 | — | — | US | disclosed |
| WO-2015166289-A1 | PYRROLOBENZODIAZEPINE COMPOUNDS | FEMTOGENIX LIMITED (GB) | 2015-11-05 | — | — | WO | disclosed |
| US-20150307541-A1 | WATER-SOLUBLE PHOTOCHROMIC MOLECULES | RIKKYO EDUCATIONAL CORPORATION (JP) | 2015-10-29 | — | — | US | disclosed |
| EP-2935268-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MedImmune Limited (GB) | 2015-10-28 | — | — | EP | disclosed |
| EP-2935273-A1 | UNSYMMETRICAL PYRROLOBENZODIAZEPINES-DIMERS FOR USE IN THE TREATMENT OF PROLIFERATIVE AND AUTOIMMUNE DISEASES | MedImmune Limited (GB) | 2015-10-28 | — | — | EP | disclosed |
| US-9169235-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2015-10-27 | — | — | US | disclosed |
| US-20150297746-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2015-10-22 | — | — | US | disclosed |
| WO-2015159076-A1 | HUMANIZED ANTI-TN-MUC1 ANTIBODIES AND THEIR CONJUGATES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-10-22 | — | — | WO | disclosed |
| US-20150299232-A1 | GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2015-10-22 | — | — | US | disclosed |
| EP-2350080-B1 | UNSYMMETRICAL PYRROLOBENZODIAZEPINE-DIMERS FOR TREATMENT OF PROLIFERATIVE DISEASES | SPIROGEN SARL (CH) | 2015-10-14 | — | — | EP | disclosed |
| US-20150283258-A1 | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | MEDIMMUNE LIMITED (GB) | 2015-10-08 | — | — | US | disclosed |
| US-20150283263-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | MEDIMMUNE LIMITED (GB) | 2015-10-08 | — | — | US | disclosed |
| US-20150283262-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2015-10-08 | — | — | US | disclosed |
| US-20150274737-A1 | SYNTHESIS AND INTERMEDIATES OF PYRROLOBENZODIAZEPINE DERIVATIVES FOR CONJUGATION | MEDIMMUNE LIMITED (GB) | 2015-10-01 | — | — | US | disclosed |
| US-20150273078-A1 | PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2015-10-01 | — | — | US | disclosed |
| US-20150273077-A1 | PYRROLOBENZODIAZEPINE-ANTI-HER2 ANTIBODY CONJUGATES | MEDIMMUNE LIMITED (GB) | 2015-10-01 | — | — | US | disclosed |
| US-20150265722-A1 | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2015-09-24 | — | — | US | disclosed |
| WO-2015140572-A1 | FLUORINATION METHOD | ISIS INNOVATION LIMITED (GB) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015143382-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2015-09-24 | — | — | WO | disclosed |
| EP-2750713-B1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN SARL (CH) | 2015-09-16 | — | — | EP | disclosed |
| CN-101754769-B | Use of type B lantibiotics based on antimicrobial activity | NOVACTA BIOSYSTEMS LTD. (GB) | 2015-09-09 | — | — | CN | disclosed |
| EP-2912043-A1 | NEW ANTIBACTERIAL COMPOUNDS AND BIOLOGICAL APPLICATIONS THEREOF | LABORATOIRE BIODIM (FR) | 2015-09-02 | — | — | EP | disclosed |
| CN-103087841-B | The method of liquid detergent compositions, its purposes, preparation method, test kit and washing articles | BEIJING CONFLE TECHNOLOGY CO., LTD. (CN) | 2015-09-02 | — | — | CN | disclosed |
| CN-103087847-B | A kind of method of germicidal detergent composition, its purposes, preparation method and washing object | BEIJING CONFLE TECHNOLOGY CO., LTD. (CN) | 2015-09-02 | — | — | CN | disclosed |
| EP-2906251-A1 | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | ADC Therapeutics S.a.r.l. (CH) | 2015-08-19 | — | — | EP | disclosed |
| EP-2906252-A1 | PYRROLOBENZODIAZEPINE-ANTI-HER2 ANTIBODY CONJUGATES | ADC Therapeutics S.a.r.l. (CH) | 2015-08-19 | — | — | EP | disclosed |
| EP-2906253-A1 | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES | ADC Therapeutics S.a.r.l. (CH) | 2015-08-19 | — | — | EP | disclosed |
| EP-2906249-A1 | SYNTHESIS AND INTERMEDIATES OF PYRROLOBENZODIAZEPINE DERIVATIVES FOR CONJUGATION | Spirogen Sàrl (CH) | 2015-08-19 | — | — | EP | disclosed |
| EP-2906250-A1 | PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES | ADC Therapeutics S.a.r.l. (CH) | 2015-08-19 | — | — | EP | disclosed |
| EP-2906298-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | ADC Therapeutics S.a.r.l. (CH) | 2015-08-19 | — | — | EP | disclosed |
| EP-2906296-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | ADC Therapeutics S.a.r.l. (CH) | 2015-08-19 | — | — | EP | disclosed |
| EP-2906297-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | ADC Therapeutics S.a.r.l. (CH) | 2015-08-19 | — | — | EP | disclosed |
| US-9102704-B2 | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines | SPIROGEN SARL (CH) | 2015-08-11 | — | — | US | disclosed |
| US-9102670-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2015-08-11 | — | — | US | disclosed |
| EP-2902402-A1 | WATER-SOLUBLE PHOTOCHROMIC MOLECULE | Rikkyo Educational Corporation (JP) | 2015-08-05 | — | — | EP | disclosed |
| US-20150209444-A1 | BENZODIAZEPINES AND CONJUGATES THEREOF | IMMUNOGEN, INC. (US) | 2015-07-30 | — | — | US | disclosed |
| EP-1812433-B1 | IMIDAZO[4,5-B]PYRIDIN-2-ONE AND OXAZOLO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC COMPOUNDS | CANCER REC TECH LTD (GB) | 2015-07-22 | — | — | EP | disclosed |
| CN-103087842-B | Germicidal detergent composition, application thereof, preparation method thereof, kit thereof and method thereof for cleaning object | BEIJING CONFLE TECHNOLOGY CO LTD | 2015-07-22 | — | — | CN | disclosed |
| US-20150183883-A1 | ANTI-ETBR ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH INC (US) | 2015-07-02 | — | — | US | disclosed |
| CN-104717979-A | Anti-ETBR antibodies and immunoconjugates | GENENTECH INC | 2015-06-17 | — | — | CN | disclosed |
| US-20150158869-A1 | PYRROLOBENZODIAZEPINES AS UNSYMMETRICAL DIMERIC PBD COMPOUNDS FOR INCLUSION IN TARGETED CONJUGATES | MEDIMMUNE LIMITED (GB) | 2015-06-11 | — | — | US | disclosed |
| EP-2879708-A2 | ANTI-ETBR ANTIBODIES AND IMMUNOCONJUGATES | Genentech, Inc. (US) | 2015-06-10 | — | — | EP | disclosed |
| CN-104684914-A | Pyrrolobenzodiazepines | SPIROGEN LTD | 2015-06-03 | — | — | CN | disclosed |
| US-20150133435-A1 | PYRROLOBENZODIAZEPINES | MEDIMMUNE LIMITED (GB) | 2015-05-14 | — | — | US | disclosed |
| EP-2869849-A1 | IMMUNOCONJUGATES COMPRISING ANTI-CD22 ANTIBODIES | Genentech, Inc. (US) | 2015-05-13 | — | — | EP | disclosed |
| EP-2869850-A1 | IMMUNOCONJUGATES COMPRISING ANTI-CD79B ANTIBODIES | Genentech, Inc. (US) | 2015-05-13 | — | — | EP | disclosed |
| US-20150126495-A1 | PYRROLOBENZODIAZEPINES | MEDIMMUNE LIMITED (GB) | 2015-05-07 | — | — | US | disclosed |
| US-20150111880-A1 | UNSYMMETRICAL PYRROLOBENZODIAZEPINE-DIMERS FOR TREATMENT OF PROLIFERATIVE DISEASES | MEDIMMUNE LIMITED (GB) | 2015-04-23 | — | — | US | disclosed |
| CN-104540526-A | Immunoconjugates comprising anti-CD 79B antibodies | GENENTECH INC | 2015-04-22 | — | — | CN | disclosed |
| US-9006425-B2 | Aluminum complexes and their use in the synthesis of cyclic carbonates | UNIVERSITY OF YORK (GB) | 2015-04-14 | — | — | US | disclosed |
| EP-2855481-A1 | PYRROLOBENZODIAZEPINES | UCL Business PLC (GB) | 2015-04-08 | — | — | EP | disclosed |
| EP-2855482-A1 | PYRROLOBENZODIAZEPINES | Spirogen Sàrl (CH) | 2015-04-08 | — | — | EP | disclosed |
| US-8980639-B2 | Oxidation state sensors and methods for transition metal alloys | ROLLS-ROYCE PLC (GB) | 2015-03-17 | — | — | US | disclosed |
| WO-2015018855-A1 | PENTAFLUOROETHYLATING COMPOSITIONS | FUNDACIÓ INSTITUT CATALÀ D'INVESTIGACIÓ QUÍMICA (ES) | 2015-02-12 | — | — | WO | disclosed |
| EP-1723152-B1 | Pyrrolobenzodiazepines | SPIROGEN SARL (CH) | 2015-02-11 | — | — | EP | disclosed |
| EP-2835374-A1 | Pentafluoroethylating compositions | Fundació Institut Català d'Investigació Química (ES) | 2015-02-11 | — | — | EP | disclosed |
| US-8940733-B2 | Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases | SPIROGEN SARL (CH) | 2015-01-27 | — | — | US | disclosed |
| US-20140378442-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2014-12-25 | — | — | US | disclosed |
| US-8912187-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2014-12-16 | — | — | US | disclosed |
| CN-102356086-B | Aluminum complexes and their use in the synthesis of cyclic carbonates | UNIV NEWCASTLE | 2014-11-05 | — | — | CN | disclosed |
| US-20140323726-A1 | Methods for synthesizing molybdopterin precursor Z derivatives | ALEXION PHARMA INTERNATIONAL SÀRL (CH) | 2014-10-30 | — | — | US | disclosed |
| US-20140323726-A1 | Methods for synthesizing molybdopterin precursor Z derivatives | ALEXION PHARMA INTERNATIONAL SÀRL (CH) | 2014-10-30 | — | — | US | disclosed |
| EP-2794624-A1 | GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS | Geron Corporation (US) | 2014-10-29 | — | — | EP | disclosed |
| US-20140308687-A1 | Method and Use of Metabolites for the Diagnosis and Differentiation of Neonatal Encephalopathy | INFANDX AG (DE) | 2014-10-16 | — | — | US | disclosed |
| EP-2789622-A1 | Pyrrolobenzodiazepines used to treat proliferative diseases | Spirogen Sàrl (CH) | 2014-10-15 | — | — | EP | disclosed |
| EP-2257559-B1 | SYNTHESIS OF CYCLIC CARBONATES | UNIV YORK (GB) | 2014-10-15 | — | — | EP | disclosed |
| US-20140302066-A1 | PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES | SEAGEN INC. | 2014-10-09 | — | — | US | disclosed |
| US-20140303367-A1 | Methods for Synthesizing Molybdopterin Precursor Z Derivatives | ALEXION PHARMA INTERNATIONAL SÀRL (CH) | 2014-10-09 | — | — | US | disclosed |
| US-20140303367-A1 | Methods for Synthesizing Molybdopterin Precursor Z Derivatives | ALEXION PHARMA INTERNATIONAL SÀRL (CH) | 2014-10-09 | — | — | US | disclosed |
| WO-2014159981-A2 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN SARL (CH) | 2014-10-02 | — | — | WO | disclosed |
| US-20140294868-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| US-20140286970-A1 | PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES | SEAGEN INC. | 2014-09-25 | — | — | US | disclosed |
| US-8841099-B2 | Cell-based production of nonulosonates | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2014-09-23 | — | — | US | disclosed |
| WO-2014140174-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN SÀRL (CH) | 2014-09-18 | — | — | WO | disclosed |
| US-20140274907-A1 | PYRROLOBENZODIAZEPINES | SPIROGEN SARL (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140275522-A1 | SYNTHESIS METHOD AND INTERMEDIATES USEFUL IN THE PREPARATION OF PYRROLOBENZODIAZEPINES | SPIROGEN SÁRL (CH) | 2014-09-18 | — | — | US | disclosed |
| US-8829184-B2 | Intermediates useful for the synthesis of pyrrolobenzodiazepines | SPIROGEN SARL (CH) | 2014-09-09 | — | — | US | disclosed |
| EP-2408784-B1 | ALUMINUM COMPLEXES AND THEIR USE IN THE SYNTHESIS OF CYCLIC CARBONATES | UNIV YORK (GB) | 2014-08-27 | — | — | EP | disclosed |
| US-20140234346-A1 | PYRROLOBENZODIAZEPINES | SPIROGEN SÀRL (CH) | 2014-08-21 | — | — | US | disclosed |
| EP-2755642-A1 | PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES | Seattle Genetics, Inc. (US) | 2014-07-23 | — | — | EP | disclosed |
| EP-2751120-A1 | PYRROLOBENZODIAZEPINES AS UNSYMMETRICAL DIMERIC PBD COMPOUNDS FOR INCLUSION IN TARGETED CONJUGATES | Spirogen Sàrl (CH) | 2014-07-09 | — | — | EP | disclosed |
| EP-2751076-A1 | SYNTHESIS METHOD AND INTERMEDIATES USEFUL IN THE PREPARATION OF PYRROLOBENZODIAZEPINES | Spirogen Sàrl (CH) | 2014-07-09 | — | — | EP | disclosed |
| EP-2751111-A1 | PYRROLOBENZODIAZEPINES | Spirogen Sàrl (CH) | 2014-07-09 | — | — | EP | disclosed |
| EP-2751110-A1 | PYRROLOBENZODIAZEPINES | Spirogen Sàrl (CH) | 2014-07-09 | — | — | EP | disclosed |
| EP-2750713-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | Spirogen Sàrl (CH) | 2014-07-09 | — | — | EP | disclosed |
| US-20140178344-A1 | ACRYLAMIDE HYDROGELS FOR TISSUE ENGINEERING | EMPIRE TECHNOLOGY DEVELOPMENT LLC | 2014-06-26 | — | — | US | disclosed |
| WO-2014096368-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN SÀRL (CH) | 2014-06-26 | — | — | WO | disclosed |
| US-20140178344-A1 | ACRYLAMIDE HYDROGELS FOR TISSUE ENGINEERING | EMPIRE TECHNOLOGY DEVELOPMENT LLC | 2014-06-26 | — | — | US | disclosed |
| WO-2014096365-A1 | UNSYMMETRICAL PYRROLOBENZODIAZEPINES-DIMERS FOR USE IN THE TREATMENT OF PROLIFERATIVE AND AUTOIMMUNE DISEASES | SPIROGEN SÀRL (CH) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014088555-A1 | HIGH PERFORMANCE ACRYLAMIDE ADHESIVES | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014088557-A1 | ACRYLAMIDE HYDROGELS FOR TISSUE ENGINEERING | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2014-06-12 | — | — | WO | disclosed |
| US-20140155563-A1 | HIGH PERFORMANCE ACRYLAMIDE ADHESIVES | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155563-A1 | HIGH PERFORMANCE ACRYLAMIDE ADHESIVES | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140142090-A1 | UNSYMMETRICAL PYRROLOBENZODIAZEPINE-DIMERS FOR TREATMENT OF PROLIFERATIVE DISEASES | SPIROGEN SARL (CH) | 2014-05-22 | — | — | US | disclosed |
| US-8729203-B2 | Polymer composition | CONTAMAC LIMITED (GB) | 2014-05-20 | — | — | US | disclosed |
| US-20140135315-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2014-05-15 | — | — | US | disclosed |
| WO-2014067904-A1 | NEW ANTIBACTERIAL COMPOUNDS AND BIOLOGICAL APPLICATIONS THEREOF | LABORATOIRE BIODIM (FR) | 2014-05-08 | — | — | WO | disclosed |
| WO-2014057122-A1 | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | ADC THERAPEUTICS SÀRL (CH) | 2014-04-17 | — | — | WO | disclosed |
| WO-2014057072-A1 | SYNTHESIS AND INTERMEDIATES OF PYRROLOBENZODIAZEPINE DERIVATIVES FOR CONJUGATION | SPIROGEN SÀRL (CH) | 2014-04-17 | — | — | WO | disclosed |
| WO-2014057115-A1 | PYRROLOBENZODIAZEPINE-ANTI-HER2 ANTIBODY CONJUGATES | ADC THERAPEUTICS SÀRL (CH) | 2014-04-17 | — | — | WO | disclosed |
| WO-2014057118-A1 | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | ADC THERAPEUTICS SARL (CH) | 2014-04-17 | — | — | WO | disclosed |
| US-8697688-B2 | Pyrrolobenzodiazepines used to treat proliferative diseases | SEATTLE GENETICS INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20140080769-A1 | SUBSTRATE REDUCTION THERAPY | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2014-03-20 | — | — | US | disclosed |
| US-20140066435-A1 | PYRROLOBENZODIAZEPINES USED TO TREAT PROLIFERATIVE DISEASES | SPIROGEN SARL (CH) | 2014-03-06 | — | — | US | disclosed |
| US-8664372-B2 | Process for producing 1,2-trans-glycoside compound | GLYTECH, INC. (JP) | 2014-03-04 | — | — | US | disclosed |
| WO-2014022679-A2 | ANTI-ETBR ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2014-02-06 | — | — | WO | disclosed |
| US-20140030279-A1 | ANTI-CD22 ANTIBODIES AND IMMUNOCONJUGATES | SPIROGEN SARL (CH) | 2014-01-30 | — | — | US | disclosed |
| US-20140031539-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | Biocodex, Inc (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140030280-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8637664-B2 | Alkyl 4- [4- (5-oxo-2,3,5, 11a-tetrahydo-5H-pyrrolo [2, 1-c] [1,4] benzodiazepine-8-yloxy)-butyrylamino]-1H-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease | SPIROGEN SARL (CH) | 2014-01-28 | — | — | US | disclosed |
| US-8633185-B2 | Pyrrolobenzodiazepines | SPIROGEN SARL (CH) | 2014-01-21 | — | — | US | disclosed |
| WO-2014011519-A1 | IMMUNOCONJUGATES COMPRISING ANTI-CD79B ANTIBODIES | GENENTECH, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| WO-2014011518-A1 | IMMUNOCONJUGATES COMPRISING ANTI-CD22 ANTIBODIES | GENENTECH, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| US-20130317237-A1 | SYNTEHSIS OF CYCLIC CARBONATES | UNIVERSITY OF NEW CASTLE UPON TYNE (GB) | 2013-11-28 | — | — | US | disclosed |
| WO-2013177481-A1 | BENZODIAZEPINES AND CONJUGATES THEREOF | IMMUNOGEN, INC. (US) | 2013-11-28 | — | — | WO | disclosed |
| US-8592576-B2 | Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases | SPIROGEN SARL (CH) | 2013-11-26 | — | — | US | disclosed |
| EP-2662095-A1 | Pyrrolobenzodiazepines and conjugates thereof | Spirogen Sàrl (CH) | 2013-11-13 | — | — | EP | disclosed |
| WO-2013164593-A1 | PYRROLOBENZODIAZEPINES | SPIROGEN SÀRL (CH) | 2013-11-07 | — | — | WO | disclosed |
| WO-2013164592-A1 | PYRROLOBENZODIAZEPINES | UCL BUSINESS PLC (GB) | 2013-11-07 | — | — | WO | disclosed |
| US-8575094-B2 | Use of type-B lantibiotic-based compounds having antimicrobial activity | NOVACTA BIOSYSTEMS LIMITED (GB) | 2013-11-05 | — | — | US | disclosed |
| US-8557844-B2 | Substrate reduction therapy | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2013-10-15 | — | — | US | disclosed |
| US-20130266595-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130196381-A1 | CELL-BASED PRODUCTION OF NANULOSONATES | UNIVERSITY OF OTTAWA (CA) | 2013-08-01 | — | — | US | disclosed |
| US-20130190529-A1 | Fluorine Radiolabelling Process | ISIS INNOVATION LIMITED (GB) | 2013-07-25 | — | — | US | disclosed |
| US-8487092-B2 | Pyrrolobenzodiazepines | SPIROGEN DEVELOPMENTS SARL (CH) | 2013-07-16 | — | — | US | disclosed |
| EP-2528625-B1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN SARL (CH) | 2013-07-10 | — | — | EP | disclosed |
| US-20130172210-A1 | METHOD OF DRUG DESIGN | ALCHEMIA LIMITED (AU) | 2013-07-04 | — | — | US | disclosed |
| WO-2013095684-A1 | GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS | GERON CORPORATION (US) | 2013-06-27 | — | — | WO | disclosed |
| EP-2350098-B1 | PYRROLOBENZODIAZEPINES | SPIROGEN SARL (CH) | 2013-05-15 | — | — | EP | disclosed |
| EP-2590910-A2 | FLUORINE RADIOLABELLING PROCESS | Isis Innovation Limited (GB) | 2013-05-15 | — | — | EP | disclosed |
| CN-103087847-A | Germicidal detergent composition, application thereof, preparation method thereof, and method thereof for cleaning object | BEIJING CONFLE TECHNOLOGY CO LTD | 2013-05-08 | — | — | CN | disclosed |
| CN-103087842-A | Germicidal detergent composition, application thereof, preparation method thereof, kit thereof and method thereof for cleaning object | BEIJING CONFLE TECHNOLOGY CO LTD | 2013-05-08 | — | — | CN | disclosed |
| CN-103087841-A | Liquid detergent composition, and use, preparation method, kit and method for washing article thereof | BEIJING CONFLE TECHNOLOGY CO LTD | 2013-05-08 | — | — | CN | disclosed |
| US-8435985-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | MENEAR KEITH (GB) | 2013-05-07 | — | — | US | disclosed |
| CN-103068405-A | Targeted pyrrolobenzodiazepine conjugates | SEATTLE GENETICS INC | 2013-04-24 | — | — | CN | disclosed |
| US-8426345-B2 | Method of drug design | ALCHEMIA LIMITED (AU) | 2013-04-23 | — | — | US | disclosed |
| WO-2013053871-A1 | PYRROLOBENZODIAZEPINES | SPIROGEN SÀRL (CH) | 2013-04-18 | — | — | WO | disclosed |
| WO-2013055990-A1 | PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES | SEATTLE GENETICS, INC. (US) | 2013-04-18 | — | — | WO | disclosed |
| WO-2013055993-A1 | PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES | SEATTLE GENETICS, INC. (US) | 2013-04-18 | — | — | WO | disclosed |
| WO-2013055987-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN SÀRL (CH) | 2013-04-18 | — | — | WO | disclosed |
| WO-2013053872-A1 | SYNTHESIS METHOD AND INTERMEDIATES USEFUL IN THE PREPARATION OF PYRROLOBENZODIAZEPINES | SPIROGEN SÀRL (CH) | 2013-04-18 | — | — | WO | disclosed |
| WO-2013053873-A1 | PYRROLOBENZODIAZEPINES | SPIROGEN SÀRL (CH) | 2013-04-18 | — | — | WO | disclosed |
| EP-1720881-B9 | 11-HYDROXY-5H-PYRROLO[2,1-C][1,4]BENZODIAZEPIN-5-ONE DERIVATIVES AS KEY INTERMEDIATES FOR THE PREPARATION OF C2 SUBSTITUTED PYRROLOBENZODIAZEPINS | SPIROGEN SARL (CH) | 2013-04-17 | — | — | EP | disclosed |
| WO-2013041606-A1 | PYRROLOBENZODIAZEPINES AS UNSYMMETRICAL DIMERIC PBD COMPOUNDS FOR INCLUSION IN TARGETED CONJUGATES | SPIROGEN SÀRL (CH) | 2013-03-28 | — | — | WO | disclosed |
| CN-102971329-A | Pyrrolobenzodiazepines for the treatment of proliferative diseases | SPIROGEN LTD | 2013-03-13 | — | — | CN | disclosed |
| US-20130059800-A1 | PYRROLOBENZODIAZEPINES USED TO TREAT PROLIFERATIVE DISEASES | SEATTLE GENETICS INC. (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2013026454-A1 | TREATMENT OF CLINICAL CONDITIONS WITH ANTHRACYCLINES | VALDERM APS (DK) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013026453-A1 | TREATMENT OF INFLAMMATORY DISORDERS WITH ANTHRACYCLINES | VALDERM APS (DK) | 2013-02-28 | — | — | WO | disclosed |
| EP-2558445-A1 | INTERMEDIATES USEFUL FOR THE SYNTHESIS OF PYRROLOBENZODIAZEPINES | Spirogen Sàrl (CH) | 2013-02-20 | — | — | EP | disclosed |
| EP-2558475-A1 | PYRROLOBENZODIAZEPINES USED TO TREAT PROLIFERATIVE DISEASES | Spirogen Sàrl (CH) | 2013-02-20 | — | — | EP | disclosed |
| EP-2558127-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | Seattle Genetics, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20130035484-A1 | INTERMEDIATES USEFUL FOR THE SYNTHESIS OF PYRROLOBENZODIAZEPINES | SPIROGEN DEVELOPMENTS SÀRL (CH) | 2013-02-07 | — | — | US | disclosed |
| US-20130035414-A1 | HIGH REFRACTIVE INDEX POLYMER COMPOSITION FOR OPTHALMIC APPLICATIONS | CONTAMAC LIMITED (GB) | 2013-02-07 | — | — | US | disclosed |
| US-20130028917-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN DEVELOPMENTS SÀRL (CH) | 2013-01-31 | — | — | US | disclosed |
| US-20130028919-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SPIROGEN DEVELOPMENTS SÀRL (CH) | 2013-01-31 | — | — | US | disclosed |
| EP-2542595-A1 | HIGH REFRACTIVE INDEX POLYMER COMPOSITION FOR OPTHALMIC APPLICATIONS | Contamac Limited (GB) | 2013-01-09 | — | — | EP | disclosed |
| EP-1727808-B3 | BIARYL AMINO ACIDS AND THEIR USE IN DNA BINDING OLIGOMERS | SPIROGEN LTD (GB) | 2013-01-09 | — | — | EP | disclosed |
| EP-2536275-A1 | METHODS OF REDUCING VIRULENCE IN BACTERIA | UWM Research Foundation, Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| US-20120322769-A1 | METHODS OF REDUCING VIRULENCE IN BACTERIA | DUKE UNIVERSITY (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120321963-A1 | GEL POLYMER ELECTROLYTE COMPOSITION | KURARAY CO., LTD. (JP) | 2012-12-20 | — | — | US | disclosed |
| EP-1720881-B1 | 11-HYDROXY-5H-PYRROLO[2,1-C][1,4]BENZODIAZEPIN-5-ONE DERIVATIVES AS KEY INTERMEDIATES FOR THE PREPARATION OF C2 SUBSTITUTED PYRROLOBENZODIAZEPINS | SPIROGEN LTD (GB) | 2012-12-12 | — | — | EP | disclosed |
| US-8329644-B2 | Lantibiotic-based compounds having antimicrobial activity | NOVACTA BIOSYSTEMS LIMITED (GB) | 2012-12-11 | — | — | US | disclosed |
| EP-1934388-B1 | METHOD OF DRUG DESIGN | ALCHEMIA LTD (AU) | 2012-12-05 | — | — | EP | disclosed |
| EP-2528625-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | Spirogen Developments SARL (CH) | 2012-12-05 | — | — | EP | disclosed |
| CN-102796147-A | Compounds library | ALCHEMIA LTD | 2012-11-28 | — | — | CN | disclosed |
| EP-2524932-A1 | GEL POLYMER ELECTROLYTE COMPOSITION | Kuraray Co., Ltd. (JP) | 2012-11-21 | — | — | EP | disclosed |
| EP-2146977-B1 | SYNTHESIS OF CYCLIC CARBONATES IN THE PRESENCE OF DIMERIC ALUMINIUM (SALEN) CATALYSTS | UNIV NEWCASTLE (GB) | 2012-11-14 | — | — | EP | disclosed |
| EP-1954699-B1 | PYRIDO-, PYRAZO- AND PYRIMIDOPYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | KUDOS PHARM LTD (GB) | 2012-09-19 | — | — | EP | disclosed |
| CN-101278079-B | Drug design method | ALCHEMIA LTD | 2012-09-19 | — | — | CN | disclosed |
| US-20120232256-A1 | PROCESS FOR PRODUCING 1,2-TRANS-GLYCOSIDE COMPOUND | OTSUKA CHEMICAL CO., LTD. | 2012-09-13 | — | — | US | disclosed |
| US-8222381-B2 | Derivatives of monosaccharides for drug discovery | ALCHEMIA LIMITED (AU) | 2012-07-17 | — | — | US | disclosed |
| US-8212013-B2 | Phenyl 3,4,6-tri-O-benzyl-2-O-(1,1,2,2-tetramethyl-dimethylene phosphonoyl)- beta -D-thioglucopyranoside; inhibits formation of o-ester by-product resulting from the conventional glycosilation reaction of pyranose compounds of 1,2-trans form, affording 1,2-transglycoside compounds with high selectivity | OTSUKA CHEMICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20120142673-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-20120129855-A1 | PHTHALAZINONE DERIVATIVES | MENEAR KEITH ALLAN (GB) | 2012-05-24 | — | — | US | disclosed |
| US-8183202-B2 | — | — | 2012-05-22 | — | — | US | disclosed |
| EP-2013207-B1 | IMIDAZO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS | CANCER REC TECH LTD (GB) | 2012-04-25 | — | — | EP | disclosed |
| EP-2427509-A1 | POLYMER COMPOSITION | Contamac Limited (GB) | 2012-03-14 | — | — | EP | disclosed |
| US-8129380-B2 | Phthalazinone derivatives | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| US-20120053313-A1 | POLYMER COMPOSITION | CONTAMAC LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| EP-2422183-A2 | OXIDATION STATE SENSORS AND METHODS FOR TRANSITION METAL ALLOYS | Rolls-Royce PLC (GB) | 2012-02-29 | — | — | EP | disclosed |
| US-20120040467-A1 | OXIDATION STATE SENSORS AND METHODS FOR TRANSITION METAL ALLOYS | ROLLS-ROYCE PLC | 2012-02-16 | — | — | US | disclosed |
| CN-102356086-A | Aluminum complexes and their use in the synthesis of cyclic carbonates | UNIV NEWCASTLE | 2012-02-15 | — | — | CN | disclosed |
| EP-1330456-B8 | N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2012-02-08 | — | — | EP | disclosed |
| EP-2270010-B1 | 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepins | SPIROGEN LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| EP-2408784-A1 | ALUMINUM COMPLEXES AND THEIR USE IN THE SYNTHESIS OF CYCLIC CARBONATES | University Of Newcastle-Upon Tyne (GB) | 2012-01-25 | — | — | EP | disclosed |
| EP-1330456-B9 | N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| US-8101602-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | Kudos Pharmaceuticals, Ltd. (GB) | 2012-01-24 | — | — | US | disclosed |
| WO-2012004567-A2 | FLUORINE RADIOLABELLING PROCESS | ISIS INNOVATION LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| US-20120010204-A1 | Phthalazinone Derivatives | MAYBRIDGE LIMITED | 2012-01-12 | — | — | US | disclosed |
| US-8093405-B2 | Formation of 18F and 19F fluoroarenes bearing reactive functionalities | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2012-01-10 | — | — | US | disclosed |
| US-20110319634-A1 | ALUMINUM COMPLEXES AND THEIR USE IN THE SYNTHESIS OF CYCLIC CARBONATES | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2011-12-29 | — | — | US | disclosed |
| US-8071620-B2 | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-20110275576-A1 | Carbohydrate-Cyclopamine Conjugates as Anticancer Agents | UTAH STATE UNIVERSITY (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275810-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2011-11-10 | — | — | US | disclosed |
| WO-2011128650-A1 | INTERMEDIATES USEFUL FOR THE SYNTHESIS OF PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011130613-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SEATTLE GENETICS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011130616-A1 | PYRROLOBENZODIAZEPINES USED TO TREAT PROLIFERATIVE DISEASES | SPIROGEN LIMITED (GB) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011130598-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN LIMITED (GB) | 2011-10-20 | — | — | WO | disclosed |
| US-20110256157-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN LIMITED (GB) | 2011-10-20 | — | — | US | disclosed |
| WO-2011107728-A1 | HIGH REFRACTIVE INDEX POLYMER COMPOSITION FOR OPTHALMIC APPLICATIONS | CONTAMAC LIMITED (GB) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011103189-A1 | METHODS OF REDUCING VIRULENCE IN BACTERIA | UWM RESEARCH FOUNDATION, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20110201803-A1 | PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
| US-20110196148-A1 | UNSYMMETRICAL PYRROLOBENZODIAZEPINE-DIMERS FOR TREATMENT OF PROLIFERATIVE DISEASES | SPIROGEN LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| EP-2350098-A1 | PYRROLOBENZODIAZEPINES | Spirogen Limited (GB) | 2011-08-03 | — | — | EP | disclosed |
| EP-2350080-A1 | UNSYMMETRICAL PYRROLOBENZODIAZEPINE-DIMERS FOR TREATMENT OF PROLIFERATIVE DISEASES | Spirogen Limited (GB) | 2011-08-03 | — | — | EP | disclosed |
| EP-1974011-B1 | CHEMICAL INDUCTION OF QUIESCENCE IN BACTERIA | CAMBRIDGE MICROBIAL TECHNOLOGIES LTD (GB) | 2011-07-20 | — | — | EP | disclosed |
| US-7981895-B2 | Histone deacetylase inhibitor; anticancer agents; antiproliferative agents; antitumor agents; psoriasis; piperazine compound containing a carbamic acid group | TOPOTARGET UK LIMITED (GB) | 2011-07-19 | — | — | US | disclosed |
| US-7981889-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2011-07-19 | — | — | US | disclosed |
| US-7981890-B2 | Phthalazinone derivatives | ASTRAZENECA AB (SE) | 2011-07-19 | — | — | US | disclosed |
| EP-2343401-A1 | Hydrophobic surface | Rolls-Royce plc (GB) | 2011-07-13 | — | — | EP | disclosed |
| EP-2343400-A1 | Hydrophobic Surface | Rolls-Royce plc (GB) | 2011-07-13 | — | — | EP | disclosed |
| US-20110160192-A1 | BIARYL AMINO ACIDS AND THEIR USE IN DNA BINDING OLIGOMERS | SPIROGEN LIMITED (GB) | 2011-06-30 | — | — | US | disclosed |
| US-20110150984-A1 | METHODS OF INCREASING THE BIOAVAILABILITY AND/OR CELLULAR UPDATE OF DRUGS | HET NEDERLANDS KANKER INSTITUUT (NL) | 2011-06-23 | — | — | US | disclosed |
| US-20110147219-A1 | HYDROPHOBIC SURFACE | ROLLS-ROYCE PLC (GB) | 2011-06-23 | — | — | US | disclosed |
| US-20110151186-A1 | HYDROPHOBIC SURFACE | ROLLS-ROYCE PLC (GB) | 2011-06-23 | — | — | US | disclosed |
| US-7964643-B2 | Biphenyl-4-sulfonic acid-(4-hydroxybutyl)-amide and derivatives; inhibits osteoclast survival, formation, and/or activity and/or inhibits bone resorption; osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease, antiinflammatory, -carcinogenic agents; immunostimulants | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2011-06-21 | — | — | US | disclosed |
| EP-1330456-B1 | N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2011-06-15 | — | — | EP | disclosed |
| US-7951819-B2 | Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B] pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-05-31 | — | — | US | disclosed |
| US-20110124638-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2011-05-26 | — | — | US | disclosed |
| US-20110105572-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2011-05-05 | — | — | US | disclosed |
| EP-1633724-B1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARM LTD (GB) | 2011-05-04 | — | — | EP | disclosed |
| US-7935836-B2 | Compounds comprising a linear series of five fused carbon rings, and preparation thereof | FALLIS ALEXANDER GRAHAM | 2011-05-03 | — | — | US | disclosed |
| EP-2310362-A1 | FORMATION OF 18F AND 19F FLUOROARENES BEARING REACTIVE FUNCTIONALITIES | University Of Newcastle-Upon Tyne (GB) | 2011-04-20 | — | — | EP | disclosed |
| CN-102015639-A | Compounds for use in stabilizing p53 mutants | MEDICAL RES COUNCIL | 2011-04-13 | — | — | CN | disclosed |
| CN-102015732-A | Synthesis of cyclic carbonates | UNIV NEWCASTLE | 2011-04-13 | — | — | CN | disclosed |
| US-7915227-B2 | Pharmaceutical formulations employing short-chain sphingolipids and their use | HET NEDERLANDS KANKER INSTITUUT (NL) | 2011-03-29 | — | — | US | disclosed |
| EP-1432669-B1 | 4-(C2-6 ALKOXY)-SUBSTITUTED CHALCONES AS THERAPEUTIC AGENTS | SPEAR THERAPEUTICS LTD (GB) | 2011-03-23 | — | — | EP | disclosed |
| US-20110059953-A1 | COMPOUNDS FOR USE IN STABILIZING P53 MUTANTS | MEDICAL RESEARCH COUNCIL (GB) | 2011-03-10 | — | — | US | disclosed |
| EP-2292593-A2 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TopoTarget UK Limited (GB) | 2011-03-09 | — | — | EP | disclosed |
| US-7902193-B2 | Phthalazinone derivatives | MAYBRIDGE LIMITED (GB) | 2011-03-08 | — | — | US | disclosed |
| US-7902189-B2 | antitumor agent, anticarcinogenic agents; 7-Chloro-2-((2S,6R)-2,6-dimethyl-morpholin-4-yl)-4-morpholin-4-yl-pyrido[2,3-d]pyrimidine; inhibitors of mTOR kinase | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| EP-1723151-B1 | PYRROLOBENZODIAZEPINES AS KEY INTERMEDIATES IN THE SYNTHESIS OF DIMERIC CYTOTOXIC PYRROLOBENZODIAZEPINES | SPIROGEN LTD (GB) | 2011-02-16 | — | — | EP | disclosed |
| EP-1575955-B1 | PYRROLOBENZODIAZEPINES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | SPIROGEN LTD (GB) | 2011-02-09 | — | — | EP | disclosed |
| EP-1831184-B1 | PYRAZINES AND PYRIDINES AND DERIVATIVES THEREOF AS THERAPEUTIC COMPOUNDS | WELLCOME TRUST LTD (GB) | 2011-02-09 | — | — | EP | disclosed |
| US-7880020-B2 | e.g trichlorostatin A; antiproliferative agent; for treating cancer and psoriasis | TOPOTARGET UK LIMITED (GB) | 2011-02-01 | — | — | US | disclosed |
| US-20110015409-A1 | SYNTHESIS OF CYCLIC CARBONATES | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2011-01-20 | — | — | US | disclosed |
| EP-2274282-A1 | COMPOUNDS FOR USE IN STABILIZING P53 MUTANTS | Medical Research Council (GB) | 2011-01-19 | — | — | EP | disclosed |
| EP-2270010-A1 | 11-HYDROXY-5H-PYRROLO[2,1-C][1,4]BENZODIAZEPIN-5-ONE DERIVATIVES AS KEY INTERMEDIATES FOR THE PREPARATION OF C2 SUBSTITUTED PYRROLOBENZODIAZEPINS | Spirogen Limited (GB) | 2011-01-05 | — | — | EP | disclosed |
| EP-2257559-A1 | SYNTHESIS OF CYCLIC CARBONATES | University Of Newcastle-Upon Tyne (GB) | 2010-12-08 | — | — | EP | disclosed |
| WO-2010133851-A1 | PREPARATION OF LABELLED COMPOUNDS | ISIS INNOVATION LIMITED (GB) | 2010-11-25 | — | — | WO | disclosed |
| CN-101896180-A | Combination 059 | ASTRAZENECA AB | 2010-11-24 | — | — | CN | disclosed |
| WO-2010128266-A1 | POLYMER COMPOSITION | CONTAMAC LIMITED (GB) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010122287-A2 | OXIDATION STATE SENSORS AND METHODS FOR TRANSITION METAL ALLOYS | ROLLS-ROYCE PLC (GB) | 2010-10-28 | — | — | WO | disclosed |
| US-20100261638-A1 | LANTIBIOTIC-BASED COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY | NOVACTA BIOSYSTEMS LIMITED (GB) | 2010-10-14 | — | — | US | disclosed |
| CN-101084217-B | Imidazo [4,5-B] pyridin-2-ones and oxazolido [4,5-B] pyridin-2-ones and analogues thereof as therapeutic compounds | CANCER REC TECH LTD | 2010-10-13 | — | — | CN | disclosed |
| US-20100249112-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | ASTRAZENECA R&D (SE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249197-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2010-09-30 | — | — | US | disclosed |
| US-20100249234-A1 | METHODS OF REDUCING VIRULENCE IN BACTERIA | UWM RESEARCH FOUNDATION, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| EP-2231638-A1 | PHTHALAZINONE DERIVATIVES | AstraZeneca AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| WO-2010106324-A1 | ALUMINUM COMPLEXES AND THEIR USE IN THE SYNTHESIS OF CYCLIC CARBONATES | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2010-09-23 | — | — | WO | disclosed |
| US-7790435-B2 | Chemical induction in quiescence in bacteria | CAMBRIDGE MICROBIAL TECHNOLOGIES LIMITED (GB) | 2010-09-07 | — | — | US | disclosed |
| US-7781411-B2 | Derivatives of avermectin, avermectin monosaccharide and avermectin aglycone | SYNGENTA CROP PROTECTION, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| EP-2217234-A2 | COMBINATIONS OF MEK INHIBITORS WITH MTOR INHIBITORS | AstraZeneca AB (SE) | 2010-08-18 | — | — | EP | disclosed |
| US-20100204162-A1 | SUBSTRATE REDUCTION THERAPY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2010-08-12 | — | — | US | disclosed |
| US-20100203650-A1 | BIOMOLECULE BINDING LIGANDS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-08-12 | — | — | US | disclosed |
| CN-101796067-A | Lantibiotic-based compounds with antimicrobial activity | NOVACTA BIOSYSTEMS LTD | 2010-08-04 | — | — | CN | disclosed |
| CN-101796066-A | Biomolecule binding ligands | CAMBRIDGE ENTPR LTD | 2010-08-04 | — | — | CN | disclosed |
| WO-2010080817-A2 | CARBOHYDRATE-CYCLOPAMINE CONJUGATES AS ANTICANCER AGENTS | UTAH STATE UNIVERSITY (US) | 2010-07-15 | — | — | WO | disclosed |
| US-7745424-B2 | Alkane diol derivatives as therapeutic agents for the treatment of bone conditions | The Univeristy Court of the University of Aberdeen (GB) | 2010-06-29 | — | — | US | disclosed |
| CN-101754769-A | Use of type B lantibiotics based on antimicrobial activity | NOVACTA BIOSYSTEMS LTD | 2010-06-23 | — | — | CN | disclosed |
| US-7741319-B2 | 11-hydroxy-5h-pyrrolo[2,1-c][1,4] benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2010-06-22 | — | — | US | disclosed |
| US-7737152-B2 | 6-carboaryl-oxy-pyrazin-2-yl-carboaryl-amines and compositions comprising said compounds | THE WELLCOME TRUST LIMITED (GB) | 2010-06-15 | — | — | US | disclosed |
| US-20100144651-A1 | NOVEL GLUCOPYRANOSE ESTERS AND GLUCOFURANOSE ESTERS OF ALKYL- FUMARATES AND THEIR PHARMACEUTICAL USE | ADITECH PHARMA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100130473-A1 | COMPOUNDS | HUMMERSONE MARC GEOFFREY | 2010-05-27 | — | — | US | disclosed |
| US-20100130752-A1 | SYNTHESIS OF CYCLIC CARBONATES | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2010-05-27 | — | — | US | disclosed |
| EP-2188278-A1 | PHTHALAZINONE DERIVATIVES | AstraZeneca AB (SE) | 2010-05-26 | — | — | EP | disclosed |
| EP-2186819-A1 | Novel glucopyranose esters and glucofuranose esters of alkyl- fumarates and their pharmaceutical use | Aditech Pharma AG (CH) | 2010-05-19 | — | — | EP | disclosed |
| EP-2182936-A2 | SUBSTRATE REDUCTION THERAPY | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2010-05-12 | — | — | EP | disclosed |
| US-20100113425-A1 | PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2010-05-06 | — | — | US | disclosed |
| EP-2178552-A1 | THE USE OF TYPE-B LANTIBIOTIC-BASED COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY | Novacta Biosystems Limited (GB) | 2010-04-28 | — | — | EP | disclosed |
| WO-2010043880-A1 | UNSYMMETRICAL PYRROLOBENZODIAZEPINE-DIMERS FOR TREATMENT OF PROLIFERATIVE DISEASES | SPIROGEN LIMITED (GB) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010043877-A1 | PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2010-04-22 | — | — | WO | disclosed |
| EP-2176237-A1 | PHTHALAZINONE DERIVATIVES AS INHIBITORS OF PARP-1 | AstraZeneca AB (SE) | 2010-04-21 | — | — | EP | disclosed |
| US-20100093743-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| EP-2170927-A2 | BIOMOLECULE BINDING LIGANDS | Cambridge Enterprise Limited (GB) | 2010-04-07 | — | — | EP | disclosed |
| EP-2167086-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | AstraZeneca AB (SE) | 2010-03-31 | — | — | EP | disclosed |
| EP-2167527-A2 | LANTIBIOTIC-BASED COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY | Novacta Biosystems Limited (GB) | 2010-03-31 | — | — | EP | disclosed |
| WO-2010024783-A1 | BIARYLRHODANINE AND PYRIDYLRHODANINE COMPOUNDS AND THEIR USE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-03-04 | — | — | WO | disclosed |
| EP-2155726-A1 | PHTHALAZINONE DERIVATIVES AND THEIR USE AS MEDICAMENT TO TREAT CANCER | Kudos Pharmaceuticals Limited (GB) | 2010-02-24 | — | — | EP | disclosed |
| US-7666870-B2 | Phthalazinone derivatives | MAYBRIDGE LIMITED (GB) | 2010-02-23 | — | — | US | disclosed |
| US-7662818-B2 | e.g. 4-[5-(piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; and multiple sclerosis | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-02-16 | — | — | US | disclosed |
| EP-1404659-B1 | 4-ARYL QUINOLS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2010-02-10 | — | — | EP | disclosed |
| US-20100028262-A1 | 3,4-METHYLENEDIOXY-SUBSTITUTED CHALCONES AS THERAPEUTIC AGENTS | SPEAR THERAPEUTICS LIMITED (GB) | 2010-02-04 | — | — | US | disclosed |
| US-7655809-B2 | Compounds comprising a linear series of five fused carbon rings, and preparation thereof | UNIVERSITY OF OTTAWA (CA) | 2010-02-02 | — | — | US | disclosed |
| US-20100022620-A1 | EPITOPE REDUCTION THERAPY | ISIS INNOVATION LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| EP-2146977-A1 | SYNTHESIS OF CYCLIC CARBONATES IN THE PRESENCE OF DIMERIC ALUMINIUM (SALEN) CATALYSTS | University Of Newcastle-Upon Tyne (GB) | 2010-01-27 | — | — | EP | disclosed |
| US-7652036-B2 | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2010-01-26 | — | — | US | disclosed |
| WO-2010007363-A2 | PREPARATION OF FLUORINE-LABELLED COMPOUNDS | ISIS INNOVATION LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
| EP-1915387-B1 | NOVEL GLUCOPYRANOSE ESTERS AND GLUCOFURANOSE ESTERS OF ALKYL- FUMARATES AND THEIR PHARMACEUTICAL USE | ADITECH PHARMA AG (CH) | 2010-01-20 | — | — | EP | disclosed |
| US-20100004467-A1 | COMPOUNDS COMPRISING A LINEAR SERIES OF FIVE FUSED CARBON RINGS, AND PREPARATION THEREOF | FALLIS ALEXANDER GRAHAM | 2010-01-07 | — | — | US | disclosed |
| US-20090325945-A1 | IMIDAZO[4, 5-B]PYRIDIN-2-ONE AND OXAZOLO[4, 5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2009-12-31 | — | — | US | disclosed |
| EP-1664049-B1 | SYNTHESIS OF PROTECTED PYRROLOBENZODIAZEPINES | SPIROGEN LTD (GB) | 2009-12-23 | — | — | EP | disclosed |
| WO-2009153566-A1 | CYP26 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
| EP-1879901-B1 | PYRROLOBENZODIAZEPINES | SPIROGEN LTD (GB) | 2009-12-23 | — | — | EP | disclosed |
| EP-1737812-B1 | METHODS OF AMINATION | ASTRAZENECA UK LTD (GB) | 2009-12-16 | — | — | EP | disclosed |
| EP-1756046-B1 | ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | UNIV ABERDEEN (GB) | 2009-12-09 | — | — | EP | disclosed |
| US-7629343-B2 | Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2009-12-08 | — | — | US | disclosed |
| US-7625922-B2 | Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-12-01 | — | — | US | disclosed |
| WO-2009141627-A1 | TREATING NIEMANN-PICK DISEASE TYPE C AND RELATED DISORDERS BY ELEVATING INTRACELLULAR CALCIUM | ISIS INNOVATION LIMITED (GB) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009138708-A1 | BICYCLIC MONOPHOSPHINES | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009138763-A1 | FORMATION OF 18F AND 19F FLUOROARENES BEARING REACTIVE FUNCTIONALITIES | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2009-11-19 | — | — | WO | disclosed |
| US-20090286992-A1 | FORMATION OF 18F AND 19F FLUOROARENES BEARING REACTIVE FUNCTIONALITIES | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2009-11-19 | — | — | US | disclosed |
| US-20090281086-A1 | 2 -OXYHETEROARYLAMIDE DERIVATIVES AS PARP INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| WO-2009136175-A1 | COMPOUNDS FOR USE IN STABILIZING P53 MUTANTS | MEDICAL RESEARCH COUNCIL (GB) | 2009-11-12 | — | — | WO | disclosed |
| US-7612062-B2 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-7598294-B2 | Antiproliferative agents; antiinflammatory agents; anticancer agents; diagnosis, therapy | SPEAR THERAPEUTICS LIMITED (GB) | 2009-10-06 | — | — | US | disclosed |
| US-7598289-B2 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2009-10-06 | — | — | US | disclosed |
| WO-2009109765-A1 | SYNTHESIS OF CYCLIC CARBONATES | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2009-09-11 | — | — | WO | disclosed |
| US-20090209520-A1 | 2 -OXYBENZAMIDE DERIVATIVES AS PARP INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-08-20 | — | — | US | disclosed |
| US-20090209535-A1 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | TOPOTARGET A/S (DK) | 2009-08-20 | — | — | US | disclosed |
| US-20090203583-A1 | Use of Type-B Lantibiotic-Based Compounds having Antimicrobial Activity | NOVACTA BIOSYSTEMS LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-7572825-B2 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2009-08-11 | — | — | US | disclosed |
| US-7569724-B2 | Carbamic acid compounds comprising an amide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2009-08-04 | — | — | US | disclosed |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| WO-2009093032-A1 | PHTHALAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | WO | disclosed |
| EP-2083005-A1 | Carbamic acid compounds comprising an amide linkage as HDAC inhibitors | TopoTarget UK Limited (GB) | 2009-07-29 | — | — | EP | disclosed |
| EP-1572197-B1 | 4- 1- (SULFONYL) -1H-INDOL-2-YL)-4- (HYDROXY) -CYCLOHEXA-2,5-DIENONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2009-07-29 | — | — | EP | disclosed |
| US-20090186897-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20090181951-A1 | PARP INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-16 | — | — | US | disclosed |
| US-7557140-B2 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2009-07-07 | — | — | US | disclosed |
| US-7557099-B2 | Pyrrolobenzodiazepines as key intermediates in the synthesis of dimeric cytotoxic pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2009-07-07 | — | — | US | disclosed |
| US-20090163477-A1 | PHTHALAZINONE DERIVATIVES | MAYBRIDGE LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| US-20090163373-A1 | Method of Drug Design | ALCHEMIA LIMITED (AU) | 2009-06-25 | — | — | US | disclosed |
| EP-1686959-B1 | PHARMACEUTICAL FORMULATIONS EMPLOYING SHORT-CHAIN SPHINGOLIPIDS AND THEIR USE | HET NL KANKER I THE NETHERLAND (NL) | 2009-06-24 | — | — | EP | disclosed |
| WO-2009060208-A1 | PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009060215-A1 | POLYAMIDES | SPIROGEN LIMITED (GB) | 2009-05-14 | — | — | WO | disclosed |
| EP-2057156-A1 | 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | Kudos Pharmaceuticals Limited (GB) | 2009-05-13 | — | — | EP | disclosed |
| EP-1598067-B1 | Carbamic acid compounds comprising an amide linkage for the treatment of malaria | TOPOTARGET UK LTD (GB) | 2009-05-06 | — | — | EP | disclosed |
| US-7528126-B2 | Pyrrolobenzodiazepines | SPIROGEN LIMITED | 2009-05-05 | — | — | US | disclosed |
| EP-2051708-A2 | EPITOPE REDUCTION THERAPY | ISIS Innovation Limited (GB) | 2009-04-29 | — | — | EP | disclosed |
| WO-2009050506-A2 | COMBINATION 059 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099174-A1 | COMBINATION 059 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| WO-2009044130-A1 | BIARYL DIPHOSPHINES | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2009-04-09 | — | — | WO | disclosed |
| EP-1931671-B1 | ALKYL 4- [4- (5-OXO-2, 3, 5, 11A-TETRAHYD0-5H-PYRR0L0 [2, 1-C][1, 4]BENZODIAZEPINE-8-YLOXY) -BUTYRYLAMINO]-1H-PYRROLE-2-CARBOXYLATE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF A PROLIFERATIVE DISEASE | SPIROGEN LTD (GB) | 2009-04-08 | — | — | EP | disclosed |
| EP-2041087-A1 | 2 -OXYBENZAMIDE DERIVATIVES AS PARP INHIBITORS | Kudos Pharmaceuticals Limited (GB) | 2009-04-01 | — | — | EP | disclosed |
| EP-2041110-A1 | 2 -OXYHETEROARYLAMIDE DERIVATIVES AS PARP INHIBITORS | Kudos Pharmaceuticals Limited (GB) | 2009-04-01 | — | — | EP | disclosed |
| WO-2009034326-A1 | PHTHALAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | WO | disclosed |
| EP-2035380-A2 | PARP INHIBITORS | Kudos Pharmaceuticals Limited (GB) | 2009-03-18 | — | — | EP | disclosed |
| US-7504397-B2 | mTOR inhibitor compounds | KUDOS PHARMACEUTICALS LTD. (GB) | 2009-03-17 | — | — | US | disclosed |
| US-20090069303-A1 | PHTHALAZINONE DERIVATIVES | MAYBRIDGE LIMITED (GB) | 2009-03-12 | — | — | US | disclosed |
| US-20090023727-A1 | PHTHALAZINONE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| WO-2009010763-A1 | THE USE OF TYPE-B LANTIBIOTIC-BASED COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY | NOVACTA BIOSYSTEMS LIMITED (GB) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009010765-A2 | LANTIBIOTIC-BASED COMPOUNDS HAVING ANTIMICROBIAL ACTIVITY | NOVACTA BIOSYSTEMS LIMITED (GB) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009007676-A2 | BIOMOLECULE BINDING LIGANDS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2009-01-15 | — | — | WO | disclosed |
| EP-2013207-A1 | IMIDAZO[4, 5-B]PYRIDIN-2-ONE AND OXAZOLO[4, 5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS | Cancer Research Technology Limited (GB) | 2009-01-14 | — | — | EP | disclosed |
| WO-2009004356-A1 | PHTHALAZINONE DERIVATIVES AS INHIBITORS OF PARP-1 | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | WO | disclosed |
| US-20090004700-A1 | Chemical Induction in Quiescence in Bacteria | CAMBRIDGE MICROBIAL TECHNOLOGIES LIMITED (GB) | 2009-01-01 | — | — | US | disclosed |
| WO-2009001097-A2 | SUBSTRATE REDUCTION THERAPY | ISIS INNOVATION LIMITED (GB) | 2008-12-31 | — | — | WO | disclosed |
| US-7470688-B2 | Phthalazinone derivatives | MAYBRIDGE LIMITED (GB) | 2008-12-30 | — | — | US | disclosed |
| US-20080319001-A1 | Cancer Treatment Using Specific 3,6,9-Substituted Acridines | CANCER RESEARCH TECHNOLOGY LTD (GB) | 2008-12-25 | — | — | US | disclosed |
| US-20080312186-A1 | KETONES AND REDUCED KETONES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-12-18 | — | — | US | disclosed |
| US-7465719-B2 | Carbamic acid compounds comprising an ester or ketone linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2008-12-16 | — | — | US | disclosed |
| US-20080300134-A1 | Derivatives of Avermectin, Avermectin Monosaccharide and Avermectin Aglycone | SYNGENTA CROP PROTECTION, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| WO-2008146035-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | WO | disclosed |
| US-20080280910-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| EP-1727808-B1 | BIARYL AMINO ACIDS AND THEIR USE IN DNA BINDING OLIGOMERS | SPIROGEN LTD (GB) | 2008-11-12 | — | — | EP | disclosed |
| US-7449464-B2 | 4-{3-[4-(6-Chlorobenzothiazol-2-yl)-1,4-diazepan-1-ylcarbonyl]benzyl}-1(2H)-phthalazinone; Cancer, BRCA deficient | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-11-11 | — | — | US | disclosed |
| WO-2008132474-A1 | SYNTHESIS OF CYCLIC CARBONATES IN THE PRESENCE OF DIMERIC ALUMINIUM (SALEN) CATALYSTS | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2008-11-06 | — | — | WO | disclosed |
| US-20080267903-A1 | Cationic polyamines and dendrimeric polymers; anti-proliferative agents; for treatment of neoplasms and tumours, inflammatory disorders, autoimmune disorders, psoriasis, and atherosclerosis; gene therapy | UNIVERSITY COLLEGE LONDON (GB) | 2008-10-30 | — | — | US | disclosed |
| US-20080269237-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2008-10-30 | — | — | US | disclosed |
| US-20080255128-A1 | e.g. 4-[5-(Piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; multiple sclerosis | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| WO-2008122810-A1 | PHTHALAZINONE DERIVATIVES AND THEIR USE AS MEDICAMENT TO TREAT CANCER | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124836-A2 | METHODS OF REDUCING VIRULENCE IN BACTERIA | UWM RESEARCH FOUNDATION, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| EP-1974011-A1 | CHEMICAL INDUCTION OF QUIESCENCE IN BACTERIA | Cambridge Microbial Technologies LTD (GB) | 2008-10-01 | — | — | EP | disclosed |
| CN-101278079-A | Drug design method | ALCHEMIA LTD (AU) | 2008-10-01 | — | — | CN | disclosed |
| US-7429658-B2 | Synthesis of protected pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| WO-2008114023-A2 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-09-25 | — | — | WO | disclosed |
| US-20080214525-A1 | Alkyl 4- [4- (5-Oxo-2,3,5, 11A-Tetrahydo-5H-Pyrrolo [2, 1-C] [1,4] Benzodiazepine-8-Yloxy) -Butyrylamino]-1H-Pyrrole-2-Carboxylate Derivatives and Related Compounds For the Treatment of a Proliferative Disease | SPIROGEN LIMITED (GB) | 2008-09-04 | — | — | US | disclosed |
| US-20080200469-A1 | e.g. 4-[5-(Piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; multiple sclerosis | KUDOS PHARMACEUTICALS LIMITED | 2008-08-21 | — | — | US | disclosed |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| EP-1954699-A1 | PYRIDO-,PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | Kudos Pharmaceuticals Ltd (GB) | 2008-08-13 | — | — | EP | disclosed |
| US-7407988-B2 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2008-08-05 | — | — | US | disclosed |
| US-7407951-B2 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2008-08-05 | — | — | US | disclosed |
| US-7407957-B2 | e.g. 4-[5-(piperazine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent; septic shock; ischemic injury; reperfusion injury; hemorrhagic shock; and multiple sclerosis | MAYBRIDGE LIMITED (GB) | 2008-08-05 | — | — | US | disclosed |
| EP-1948642-A1 | 4-HETEROARYMETHYL SUBSTITUTED PHTHALAZINONE DERIVATIVES | Kudos Pharmaceuticals Ltd (GB) | 2008-07-30 | — | — | EP | disclosed |
| US-20080177049-A1 | Process for Producing 1,2-Trans-Glycoside Compound | GLYTECH, INC. (JP) | 2008-07-24 | — | — | US | disclosed |
| US-20080167293-A1 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2008-07-10 | — | — | US | disclosed |
| US-20080161401-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2008-07-03 | — | — | US | disclosed |
| EP-1934388-A1 | METHOD OF DRUG DESIGN | Alchemia Ltd (AU) | 2008-06-25 | — | — | EP | disclosed |
| EP-1492534-B1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LTD (GB) | 2008-06-25 | — | — | EP | disclosed |
| EP-1931671-A1 | ALKYL 4- [4- (5-OXO-2, 3, 5, 11A-TETRAHYD0-5H-PYRR0L0 [2, 1-C][1, 4]BENZODIAZEPINE-8-YLOXY) -BUTYRYLAMINO]-1H-PYRROLE-2-CARBOXYLATE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF A PROLIFERATIVE DISEASE | Spirogen Limited (GB) | 2008-06-18 | — | — | EP | disclosed |
| US-20080119555-A1 | Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-05-22 | — | — | US | disclosed |
| EP-1915387-A1 | NOVEL GLUCOPYRANOSE ESTERS AND GLUCOFURANOSE ESTERS OF ALKYL- FUMARATES AND THEIR PHARMACEUTICAL USE | Aditech Pharma AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| US-20080090812-A1 | Pyrrolobenzodiazepine Therapeutic Agents Useful in the Treatment of Leukemias | SPIROGEN LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-7358398-B2 | of aromatic groups using transition metal catalysis in compressed carbon dioxide; intermediates | ASTRAZENECA UK LIMITED (GB) | 2008-04-15 | — | — | US | disclosed |
| US-20080081809-A1 | Novel Compounds | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-04-03 | — | — | US | disclosed |
| WO-2008023161-A1 | 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008012555-A2 | EPITOPE REDUCTION THERAPY | ISIS INNOVATION LIMITED (GB) | 2008-01-31 | — | — | WO | disclosed |
| EP-1879901-A1 | PYRROLOBENZODIAZEPINES | Spirogen Limited (GB) | 2008-01-23 | — | — | EP | disclosed |
| US-20080015191-A1 | Pyrazines and Pyridines and Derivatives Thereof as Therapeutic Compounds | THE WELLCOME TRUST LIMITED (UK) | 2008-01-17 | — | — | US | disclosed |
| EP-1877388-A2 | HYDRAZINOMETHYL, HYDRAZONOMETHYL AND 5-MEMBERED HETEROCYLIC COMPOUNDS WHICH ACT AS MTOR INHIBITORS AND THEIR USE AS ANTI CANCER AGENTS | Kudos Pharmaceuticals Ltd (GB) | 2008-01-16 | — | — | EP | disclosed |
| US-20080009418-A1 | Selective Inhibitors | ALCHEMIA LTD. (AU) | 2008-01-10 | — | — | US | disclosed |
| EP-1871377-A1 | 2,4-DIAMINO-PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE AS MTOR INHIBITORS | Kudos Pharmaceuticals Ltd (GB) | 2008-01-02 | — | — | EP | disclosed |
| WO-2007144637-A1 | 2 -OXYHETEROARYLAMIDE DERIVATIVES AS PARP INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007144652-A2 | PARP INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007144639-A1 | 2 -OXYBENZAMIDE DERIVATIVES AS PARP INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
| US-20070287838-A1 | Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-12-13 | — | — | US | disclosed |
| US-7307099-B2 | 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-12-11 | — | — | US | disclosed |
| EP-1638544-B1 | KETONES AND REDUCED KETONES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | UNIV ABERDEEN (GB) | 2007-12-05 | — | — | EP | disclosed |
| CN-101084217-A | Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds | CANCER REC TECH LTD (GB) | 2007-12-05 | — | — | CN | disclosed |
| EP-1858856-A2 | CANCER TREATMENT USING SPECIFIC 3,6,9-SUBSTITUTED ACRIDINES | Antisoma PLC (GB) | 2007-11-28 | — | — | EP | disclosed |
| US-7300930-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-27 | — | — | US | disclosed |
| WO-2007125330-A1 | IMIDAZO[4, 5-B]PYRIDIN-2-ONE AND OXAZOLO[4, 5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| EP-1848717-A2 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | Topotarget A/S (DK) | 2007-10-31 | — | — | EP | disclosed |
| EP-1849794-A1 | PROCESS FOR PRODUCING 1,2-TRANS-GLYCOSIDE COMPOUND | Otsuka Chemical Co., Ltd. (JP) | 2007-10-31 | — | — | EP | disclosed |
| US-20070249591-A1 | Biaryl Amino Acids and Their Use in Dna Binding Oligomers | SPIROGEN LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| CN-100341885-C | Process for selective production of aryl 5-thio-beta-d-aldohexopyranosides | TAISHO PHARMACEUTICAL CO LTD (JP) | 2007-10-10 | — | — | CN | disclosed |
| EP-1456180-B1 | 3-(2,4)DIHYDROXYPHENYL-4-PHENYLPYRAZOLES AND THEIR MEDICAL USE | VERNALIS CAMBRIDGE LTD (GB) | 2007-10-03 | — | — | EP | disclosed |
| EP-1518823-B1 | METAL OXIDE NANOTUBE AND PROCESS FOR PRODUCTION THEREOF | JAPAN SCIENCE & TECH AGENCY (JP) | 2007-09-26 | — | — | EP | disclosed |
| EP-1831184-A2 | PYRAZINES AND PYRIDINES AND DERIVATIVES THEREOF AS THERAPEUTIC COMPOUNDS | The Wellcome Trust Limited (GB) | 2007-09-12 | — | — | EP | disclosed |
| CN-101036057-A | Selective inhibitors | ALCHEMIA LTD (AU) | 2007-09-12 | — | — | CN | disclosed |
| EP-1828118-A1 | PARP INHIBITORS | Kudos Pharmaceuticals Ltd (GB) | 2007-09-05 | — | — | EP | disclosed |
| US-20070191309-A1 | Pyrrolobenzodiazepines as key intermediates in the synthesis of dimeric cytotoxic pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
| US-20070191349-A1 | C8, c8' linked 5-oxo-1,2,3,11a-tetrahydro-5h-pyrrolo[2,1-c][1,4] benzodiazepine dimers with 1h-pyrrole-dicarboxylic acid amide linkers and oligomeric analogs therof as well as related compounds for the treatment of proliferative diseases | SPIROGEN LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
| WO-2007088559-A1 | PROCESS FOR PRODUCING SUBSTITUTED SULPHOXIDES | JUBILANT ORGANOSYS LIMITED (IN) | 2007-08-09 | — | — | WO | disclosed |
| US-20070185073-A1 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070179315-A1 | Methods of amination | ASTRAZENECA UK LIMITED (GB) | 2007-08-02 | — | — | US | disclosed |
| EP-1812433-A1 | IMIDAZO[4,5-B]PYRIDIN-2-ONE AND OXAZOLO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC COMPOUNDS | Cancer Research Technology Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| US-20070173497-A1 | 11-Hydroxy-5h-pyrrolo[2,1-c][1,4] benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2007-07-26 | — | — | US | disclosed |
| US-7247734-B2 | 3,4-diarylpyrazoles and their use in the therapy of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-07-24 | — | — | US | disclosed |
| EP-1807096-A1 | BIOACTIVE POLYMERS | THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2007-07-18 | — | — | EP | disclosed |
| WO-2007071959-A1 | CHEMICAL INDUCTION OF QUIESCENCE IN BACTERIA | CAMBRIDGE MICROBIAL TECHNOLOGIES LTD (GB) | 2007-06-28 | — | — | WO | disclosed |
| EP-1797428-A1 | SELECTIVE INHIBITORS | Alchemia Pty Ltd (AU) | 2007-06-20 | — | — | EP | disclosed |
| EP-1791827-A1 | 4-HETEROARYLMETHYL SUBSTITUTED PHTHALAZINONE DERIVATIVES | Kudos Pharmaceuticals Limited (GB) | 2007-06-06 | — | — | EP | disclosed |
| WO-2007060404-A1 | PYRIDO-,PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-05-31 | — | — | WO | disclosed |
| EP-1789430-A2 | DERIVATES OF AVERMECTIN,AVERMECTIN MONOSACCHARIDE AND AVERMECTIN AGLYCONE | Syngenta Participations AG (CH) | 2007-05-30 | — | — | EP | disclosed |
| WO-2007045877-A1 | 4-HETEROARYMETHYL SUBSTITUTED PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-04-26 | — | — | WO | disclosed |
| US-20070093489-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-04-26 | — | — | US | disclosed |
| US-7205311-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED | 2007-04-17 | — | — | US | disclosed |
| WO-2007039752-A1 | ALKYL 4- [4- (5-OXO-2, 3, 5, 11A-TETRAHYD0-5H-PYRR0L0 [2, 1-C] [1, 4] BENZODIAZEPINE-8-YLOXY) -BUTYRYLAMINO]-1H-PYRROLE-2-CARBOXYLATE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF A PROLIFERATIVE DISEASE | SPIROGEN LIMITED (GB) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007038829-A1 | METHOD OF DRUG DESIGN | ALCHEMIA LTD (AU) | 2007-04-12 | — | — | WO | disclosed |
| US-20070082855-A1 | Pharmaceutical formulations employing short-chain sphingolipids and their use | HET NEDERLANDS KANKER INSTITUUT (NL) | 2007-04-12 | — | — | US | disclosed |
| WO-2007029021-A1 | 1,5-SUBSTITUTED TETRAZOLES AS THERAPEUTIC COMPOUNDS | THE UNIVERSITY OF EDINBURGH (GB) | 2007-03-15 | — | — | WO | disclosed |
| EP-1755612-A2 | PYRROLOBENZODIAZEPINE THERAPEUTIC AGENTS USEFUL IN THE TREATMENT OF LEUKAEMIAS | Spirogen Limited (GB) | 2007-02-28 | — | — | EP | disclosed |
| EP-1756046-A2 | ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | The University Court of The University of Aberdeen (GB) | 2007-02-28 | — | — | EP | disclosed |
| US-7183298-B2 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2007-02-27 | — | — | US | disclosed |
| US-7172747-B2 | Metal oxide nanotube and process for production thereof | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2007-02-06 | — | — | US | disclosed |
| US-20070027112-A1 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN, THE (GB) | 2007-02-01 | — | — | US | disclosed |
| US-20070015799-A1 | Glyoxalase inhibitors | CHROMA THERAPEUTICS LIMITED (GB) | 2007-01-18 | — | — | US | disclosed |
| WO-2007006308-A1 | NOVEL GLUCOPYRANOSE ESTERS AND GLUCOFURANOSE ESTERS OF ALKYL- FU MARATES AND THEIR PHARMACEUTICAL USE | ADITECH PHARMA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007007054-A1 | PHTHALAMIDES, SUCCINIMIDES AND RELATED COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-01-18 | — | — | WO | disclosed |
| US-7160896-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-01-09 | — | — | US | disclosed |
| US-20070004806-A1 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2007-01-04 | — | — | US | disclosed |
| EP-1737812-A1 | METHODS OF AMINATION | AstraZeneca UK Limited (GB) | 2007-01-03 | — | — | EP | disclosed |
| US-20060287396-A1 | 4-aryl quinols and analogs thereof as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-12-21 | — | — | US | disclosed |
| EP-1727808-A2 | BIARYL AMINO ACIDS AND THEIR USE IN DNA BINDING OLIGOMERS | Spirogen Limited (GB) | 2006-12-06 | — | — | EP | disclosed |
| US-7144893-B2 | 4-aryl quinols and analogs thereof as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-12-05 | — | — | US | disclosed |
| US-20060267004-A1 | Compounds comprising a linear series of five fused carbon rings, and preparation thereof | UNIVERSITY OF OTTAWA (CA) | 2006-11-30 | — | — | US | disclosed |
| US-20060264622-A1 | Synthesis of protected pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
| EP-1723152-A1 | PYRROLOBENZODIAZEPINES | Spirogen Limited (GB) | 2006-11-22 | — | — | EP | disclosed |
| EP-1723151-A2 | PYRROLOBENZODIAZEPINES AS KEY INTERMEDIATES IN THE SYNTHESIS OF DIMERIC CYTOTOXIC PYRROLOBENZODIAZEPINES | Spirogen Limited (GB) | 2006-11-22 | — | — | EP | disclosed |
| EP-1720880-A1 | C8, C8' LINKED 5-OXO-1,2,3,11A-TETRAHYDRO-5H-PYRROLO[2,1-C][1,4]BENZODIAZEPINE DIMERS WITH 1H-PYRROLE-DICARBOXYLIC ACID AMIDE LINKERS AND OLIGOMERIC ANALOGS THEREOF AS WELL AS RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Spirogen Limited (GB) | 2006-11-15 | — | — | EP | disclosed |
| EP-1720881-A1 | 11-HYDROXY-5H-PYRROLO[2,1-C][1,4]BENZODIAZEPIN-5-ONE DERIVATIVES AS KEY INTERMEDIATES FOR THE PREPARATION OF C2 SUBSTITUTED PYRROLOBENZODIAZEPINS | Spirogen Limited (GB) | 2006-11-15 | — | — | EP | disclosed |
| WO-2006111759-A1 | PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2006-10-26 | — | — | WO | disclosed |
| US-20060240527-A1 | Process for producing fine self-aggregates | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2006-10-26 | — | — | US | disclosed |
| US-7115619-B2 | N8, N13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-10-03 | — | — | US | disclosed |
| US-7112698-B2 | 4-(c2-6alkoxy)-substituted chalcones as therapeutic agents | SPEAR THERAPEUTICS LIMITED (GB) | 2006-09-26 | — | — | US | disclosed |
| US-7109189-B2 | Mitochondrially targeted antioxidants | UNIVERSITY OF OTAGO (NZ) | 2006-09-19 | — | — | US | disclosed |
| WO-2006095139-A2 | CANCER TREATMENT USING SPECIFIC 3,6,9-SUBSTITUTED ACRIDINES | ANTISOMA PLC (GB) | 2006-09-14 | — | — | WO | disclosed |
| US-20060199804-A1 | Compounds | KUDOS PHARMACEUTICALS LTD (GB) | 2006-09-07 | — | — | US | disclosed |
| US-20060199803-A1 | Compounds | KUDOS PHARMACEUTICALS LTD (GB) | 2006-09-07 | — | — | US | disclosed |
| WO-2006090167-A2 | HYDRAZINOMETHYL, HYDR ZONOMETHYL AND 5-MEMBERED HETEROCYLIC COMPOUNDS WHICH ACT AS MTOR INHIBITORS AND THEIR USE AS ANTI CANCER AGENTS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006090169-A1 | 2,4-DIAMINO-PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE AS MTOR INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006085219-A2 | 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY | TOPOTARGET A/S (DK) | 2006-08-17 | — | — | WO | disclosed |
| EP-1686959-A2 | PHARMACEUTICAL FORMULATIONS EMPLOYING SHORT-CHAIN SPHINGOLIPIDS AND THEIR USE | HET NEDERLANDS KANKER INSTITUUT (The Netherlands Cancer Institute) (NL) | 2006-08-09 | — | — | EP | disclosed |
| US-20060172019-A1 | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders | ABERDEEN, THE UNIVERSITY COURT OF THE UNIVERSITY OF (GB) | 2006-08-03 | — | — | US | disclosed |
| US-20060167237-A1 | Derivatives of monosaccharides for drug discovery | ALCHEMIA LIMITED (AU) | 2006-07-27 | — | — | US | disclosed |
| US-20060149059-A1 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| WO-2006067466-A2 | PYRAZINES AND PYRIDINES AND DERIVATIVES THEREOF AS THERAPEUTIC COMPOUNDS | THE WELLCOME TRUST LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006067472-A1 | PARP INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135770-A1 | PARP inhibitors | KUDOS PHARMACEUTICALS LTD. (GB) | 2006-06-22 | — | — | US | disclosed |
| US-20060128693-A1 | Pyrrolobenzodiazepines | MEDIMMUNE LIMITED (GB) | 2006-06-15 | — | — | US | disclosed |
| EP-1664049-A1 | SYNTHESIS OF PROTECTED PYRROLOBENZODIAZEPINES | Spirogen Limited (GB) | 2006-06-07 | — | — | EP | disclosed |
| EP-1441716-B1 | ALKANE DIOL DERIVATIVES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | UNIV ABERDEEN (GB) | 2006-05-31 | — | — | EP | disclosed |
| US-20060111389-A1 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-05-25 | — | — | US | disclosed |
| US-20060100265-A1 | 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
| WO-2006043090-A1 | IMIDAZO[4,5-B]PYRIDIN-2-ONE AND OXAZOLO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006040579-A1 | BIOACTIVE POLYMERS | THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006037159-A1 | SELECTIVE INHIBITORS | ALCHEMIA LIMITED (AU) | 2006-04-13 | — | — | WO | disclosed |
| US-20060079528-A1 | (E)-3-(1,3-Benzoxazol-2-yl)-N-hydroxy-2-propenamide; Methyl (E)-3-(2-quinolinyl)-2-propenoate; histone deacetylase inhibitors; inflammatory disease; cancer | TOPOTARGET UK LIMITED (GB) | 2006-04-13 | — | — | US | disclosed |
| EP-1638544-A2 | KETONES AND REDUCED KETONES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | The University Court of The University of Aberdeen (GB) | 2006-03-29 | — | — | EP | disclosed |
| US-20060063767-A1 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LTD (GB) | 2006-03-23 | — | — | US | disclosed |
| US-20060058282-A1 | Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors | TOPOTARGET UK LIMITED (GB) | 2006-03-16 | — | — | US | disclosed |
| EP-1633724-A1 | PHTHALAZINONE DERIVATIVES | Kudos Pharmaceuticals Limited (GB) | 2006-03-15 | — | — | EP | disclosed |
| WO-2006024405-A2 | DERIVATIVES OF AVERMECTIN, AVERMECTIN MONOSACCHARIDE AND AVERMECTIN AGLYCONE | SYNGENTA PARTICIPATIONS AG (CH) | 2006-03-09 | — | — | WO | disclosed |
| EP-1632498-A1 | Derivatives of avermectin, avermectin monosaccharide and avermectin aglycone | Syngenta Participations AG (CH) | 2006-03-08 | — | — | EP | disclosed |
| WO-2006021801-A1 | 4-HETEROARYLMETHYL SUBSTITUTED PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-03-02 | — | — | WO | disclosed |
| EP-1622869-A1 | GLYOXALASE INHIBITORS | Chroma Therapeutics Limited (GB) | 2006-02-08 | — | — | EP | disclosed |
| US-6984636-B2 | Mitochondrially targeted antioxidants | MEDICAL RESEARCH COUNCIL (GB) | 2006-01-10 | — | — | US | disclosed |
| EP-1606019-A1 | CANNABINOID RECEPTOR INVERSE AGONISTS AND NEUTRAL ANTAGONISTS AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE DISORDERS | The University Court of The University of Aberdeen (GB) | 2005-12-21 | — | — | EP | disclosed |
| US-20050274945-A1 | Compounds comprising a linear series of five fused carbon rings, and preparation thereof | UNIVERSITY OF OTTAWA (CA) | 2005-12-15 | — | — | US | disclosed |
| WO-2005118528-A2 | ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2005-12-15 | — | — | WO | disclosed |
| EP-1599449-A2 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | TopoTarget UK Limited (GB) | 2005-11-30 | — | — | EP | disclosed |
| WO-2005110423-A2 | PYRROLOBENZODIAZEPINE THERAPEUTIC AGENTS USEFUL IN THE TREATMENT OF LEUKAEMIAS | SPIROGEN LIMITED (GB) | 2005-11-24 | — | — | WO | disclosed |
| EP-1335898-B1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LTD (GB) | 2005-11-23 | — | — | EP | disclosed |
| EP-1598067-A1 | Carbamic acid compounds comprising an amide linkage as HDAC inhibitors | TopoTarget UK Limited (GB) | 2005-11-23 | — | — | EP | disclosed |
| US-6960685-B2 | Carbamic acid compounds comprising an ether linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2005-11-01 | — | — | US | disclosed |
| US-20050227957-A1 | Mitochondrially targeted antioxidants | MEDICAL RESEARCH COUNCIL (GB) | 2005-10-13 | — | — | US | disclosed |
| EP-1583736-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN ESTER OR KETONE LINKAGE AS HDAC INHIBITORS | TopoTarget UK Limited (GB) | 2005-10-12 | — | — | EP | disclosed |
| US-20050222230-A1 | 3,4-diarylpyrazoles and their use in the therapy of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2005-10-06 | — | — | US | disclosed |
| WO-2005090283-A1 | METHODS OF AMINATION | ASTRAZENECA UK LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| CN-1675233-A | Process for selective production of aryl 5-thio-beta-d-aldohexopyranosides | TAISHO PHARMACEUTICAL CO LTD (JP) | 2005-09-28 | — | — | CN | disclosed |
| EP-1575955-A1 | PYRROLOBENZODIAZEPINES | Spirogen Limited (GB) | 2005-09-21 | — | — | EP | disclosed |
| WO-2005085251-A1 | 11-HYDROXY-5H-PYRROLO[2,1-C][1,4]BENZODIAZEPIN-5-ONE DERIVATIVES AS KEY INTERMEDIATES FOR THE PREPARATION OF C2 SUBSTITUTED PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005085260-A1 | PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005085177-A2 | BIARYL AMINO ACIDS AND THEIR USE IN DNA BINDING OLIGOMERS | SPIROGEN LIMITED (GB) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005085259-A2 | PYRROLOBENZODIAZEPINES AS KEY INTERMEDIATES IN THE SYNTHESIS OF DIMERIC CYTOTOXIC PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005085250-A1 | C8, C8' LINKED 5-OXO-1,2,3,11A-TETRAHYDRO-5H-PYRROLO[2,1-C][1,4]BENZODIAZEPINE DIMERS WITH 1H-PYRROLE-DICARBOXYLIC ACID AMIDE LINKERS AND OLIGOMERIC ANALOGS THEROF AS WELL AS RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | SPIROGEN LIMITED (GB) | 2005-09-15 | — | — | WO | disclosed |
| EP-1572197-A1 | 4- 1- (SULFONYL) -1H-INDOL-2-YL)-4- (HYDROXY) -CYCLOHEXA-2,5-DIENONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2005-09-14 | — | — | EP | disclosed |
| US-20050143385-A1 | Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors | TOPOTARGET UK LIMITED (GB) | 2005-06-30 | — | — | US | disclosed |
| EP-1539780-A1 | DERIVATIVES OF MONOSACCHARIDES FOR DRUG DISCOVERY | Alchemia Limited (AU) | 2005-06-15 | — | — | EP | disclosed |
| EP-1186688-B1 | Hollow fibrous organic nanotube and method for producing the same | NAT INST OF ADVANCED IND SCIEN (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-1534720-A1 | MITOCHONDRIALLY TARGETED ANTIOXIDANTS | Medical Research Council (GB) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005046637-A2 | PHARMACEUTICAL FORMULATIONS EMPLOYING SHORT-CHAIN SPHINGOLIPIDS AND THEIR USE | HET NEDERLANDS KANKER INSTITUUT (NL) | 2005-05-26 | — | — | WO | disclosed |
| US-20050107445-A1 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | PROLIFIX LIMITED (GB) | 2005-05-19 | — | — | US | disclosed |
| US-6888027-B2 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2005-05-03 | — | — | US | disclosed |
| US-20050085515-A1 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | TOPO TARGET UK LIMITED, (GB) | 2005-04-21 | — | — | US | disclosed |
| US-20050077496-A1 | Metal oxide nanotube and process for production thereof | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2005-04-14 | — | — | US | disclosed |
| US-20050070568-A1 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2005-03-31 | — | — | US | disclosed |
| EP-1518823-A1 | METAL OXIDE NANOTUBE AND PROCESS FOR PRODUCTION THEREOF | Japan Science and Technology Agency (JP) | 2005-03-30 | — | — | EP | disclosed |
| WO-2005023814-A1 | SYNTHESIS OF PROTECTED PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2005-03-17 | — | — | WO | disclosed |
| US-20050059663-A1 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2005-03-17 | — | — | US | disclosed |
| EP-1512750-A1 | PROCESS FOR PRODUCING FINE SELF-AGGREGATE | Japan Science and Technology Agency (JP) | 2005-03-09 | — | — | EP | disclosed |
| US-20050014937-A1 | Fibrous nano self-assemblies | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1492534-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TopoTarget UK Limited (GB) | 2005-01-05 | — | — | EP | disclosed |
| US-20040259957-A1 | 4-(c2-6alkoxy)-substituted chalcones as therapeutic agents | SPEAR THERAPEUTICS LIMITED (GB) | 2004-12-23 | — | — | US | disclosed |
| US-20040254149-A1 | 3, 4-Methylenedioxy-substituted chalcones as therapeutic agents | SPEAR THERAPEUTICS LIMITED (GB) | 2004-12-16 | — | — | US | disclosed |
| US-20040254151-A1 | Alkane diol derivatives as therapeutic agents for the treatment of bone conditions | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN, THE (GB) | 2004-12-16 | — | — | US | disclosed |
| WO-2004101506-A1 | GLYOXALASE INHIBITORS | CHROMA THERAPEUTICS LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
| EP-1479799-A1 | FIBROUS NANO SELF-ASSEMBLIES | Japan Science and Technology Agency (JP) | 2004-11-24 | — | — | EP | disclosed |
| WO-2004098582-A2 | KETONES AND REDUCED KETONES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2004-11-18 | — | — | WO | disclosed |
| EP-1474397-A1 | THERAPEUTIC ACRIDONE AND ACRIDINE COMPOUNDS | Cancer Research Technology Limited (GB) | 2004-11-10 | — | — | EP | disclosed |
| US-20040220236-A1 | 4-Aryl quinols and analogs thereof as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-11-04 | — | — | US | disclosed |
| US-20040198830-A1 | Carbamic acid compounds comprising an ether linkage as hdac inhibitors | TOPOTARGET UK LIMITED (GB) | 2004-10-07 | — | — | US | disclosed |
| WO-2004080976-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004078261-A1 | CANNABINOID RECEPTOR INVERSE AGONISTS AND NEUTRAL ANTAGONISTS AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE DISORDERS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2004-09-16 | — | — | WO | disclosed |
| EP-1456180-A1 | 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER | Vernalis (Oxford) Ltd (GB) | 2004-09-15 | — | — | EP | disclosed |
| WO-2004076386-A2 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004065354-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN ESTER OR KETONE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2004-08-05 | — | — | WO | disclosed |
| EP-1441716-A1 | ALKANE DIOL DERIVATIVES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | The University Court of The University of Aberdeen (GB) | 2004-08-04 | — | — | EP | disclosed |
| WO-2004056361-A1 | 4-(1-(SULFONYL)-1H-INDOL-2-YL)-4-(HYDROXY)-CYCLOHEXA-2,5-DIENONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
| EP-1432413-A2 | 3,4-METHYLENEDIOXY-SUBSTITUTED CHALCONES AS THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2004-06-30 | — | — | EP | disclosed |
| EP-1432669-A1 | 4-(C2-6 ALKOXY)-SUBSTITUTED CHALCONES AS THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2004-06-30 | — | — | EP | disclosed |
| WO-2004043963-A1 | PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2004-05-27 | — | — | WO | disclosed |
| US-20040092598-A1 | Carbamic acid compounds comprising an amide linkage as hdac inhibitors | TOPOTARGET UK LIMITED (GB) | 2004-05-13 | — | — | US | disclosed |
| US-20040077726-A1 | Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors | SWK FUNDING LLC | 2004-04-22 | — | — | US | disclosed |
| EP-1404659-A1 | 4-ARYL QUINOLS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2004-04-07 | — | — | EP | disclosed |
| US-20040063739-A1 | N8, n13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-04-01 | — | — | US | disclosed |
| WO-2004014929-A1 | DERIVATIVES OF MONOSACCHARIDES FOR DRUG DISCOVERY | ALCHEMIA LIMITED (AU) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014927-A1 | MITOCHONDRIALLY TARGETED ANTIOXIDANTS | MEDICAL RESEARCH COUNCIL (GB) | 2004-02-19 | — | — | WO | disclosed |
| US-20040029851-A1 | Mitochondrially targeted antioxidants | MEDICAL RESEARCH COUNCIL (GB) | 2004-02-12 | — | — | US | disclosed |
| EP-1363888-A2 | THERAPEUTIC ACRIDONE AND ACRIDINE COMPOUNDS | Cancer Research Technology Limited (GB) | 2003-11-26 | — | — | EP | disclosed |
| US-20030207909-A1 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-11-06 | — | — | US | disclosed |
| US-6632497-B2 | The hollow fibrous organic nanotube having an inner pore diameter of 10 to 20 nm and outer diameter of 40-80 nm, comprising an O-glycoside type glycolipid having aldose residue as glycosyl group | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2003-10-14 | — | — | US | disclosed |
| WO-2003082288-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
| EP-1335898-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | Prolifix Limited (GB) | 2003-08-20 | — | — | EP | disclosed |
| EP-1333842-A2 | USE OF CORTISOL-SEQUESTERING AGENTS FOR THE TREATMENT OF HYPERCORTISOLAEMIA RELATED DISORDERS | Akzo Nobel N.V. (NL) | 2003-08-13 | — | — | EP | disclosed |
| EP-1330456-A2 | N8,N13 -DISUBSTITUTED QUINO 4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2003-07-30 | — | — | EP | disclosed |
| WO-2003059885-A1 | THERAPEUTIC ACRIDONE AND ACRIDINE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-07-24 | — | — | WO | disclosed |
| EP-1328510-A2 | CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS | PROLIFIX LTD. (GB) | 2003-07-23 | — | — | EP | disclosed |
| WO-2003055860-A1 | 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2003-07-10 | — | — | WO | disclosed |
| WO-2003037321-A1 | ALKANE DIOL DERIVATIVES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2003-05-08 | — | — | WO | disclosed |
| WO-2003029176-A1 | 4-(C2-6ALKOXY)-SUBSTITUTED CHALCONES AS THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-04-10 | — | — | WO | disclosed |
| WO-2003028713-A2 | 3,4-METHYLENEDIOXY-SUBSTITUTED CHALCONES AS THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-04-10 | — | — | WO | disclosed |
| WO-2003004479-A1 | 4-ARYL QUINOLS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-01-16 | — | — | WO | disclosed |
| EP-1210090-A2 | USE OF CHEMICAL CHELATORS AS REVERSAL AGENTS FOR DRUG-INDUCED NEUROMUSCULAR BLOCK | Akzo Nobel N.V. (NL) | 2002-06-05 | — | — | EP | disclosed |
| WO-2002036105-A2 | USE OF CORTISOL-SEQUESTERING AGENTS FOR THE TREATMENT OF HYPERCORTISOLAEMIA RELATED DISORDERS | AKZO NOBEL N.V. (US) | 2002-05-10 | — | — | WO | disclosed |
| US-20020051881-A1 | Hollow fibrous organic nanotube and method for producing the same | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2002-05-02 | — | — | US | disclosed |
| WO-2002030879-A2 | CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS | PROLIFIX LIMITED (GB) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002030932-A2 | N8,N13-DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002026696-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | PROLIFIX LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
| WO-2002026703-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN ETHER LINKAGE AS HDAC INHIBITORS | PROLIFIX LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
| EP-1186688-A1 | Hollow fibrous organic nanotube and method for producing the same | National Institute of Advanced Industrial Science and Technology (JP) | 2002-03-13 | — | — | EP | disclosed |
| WO-2002008193-A2 | THERAPEUTIC ACRIDONE AND ACRIDINE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-01-31 | — | — | WO | disclosed |
| WO-2001012202-A2 | USE OF CHEMICAL CHELATORS AS REVERSAL AGENTS FOR DRUG-INDUCED NEUROMUSCULAR BLOCK | AKZO NOBEL N.V. (NL) | 2001-02-22 | — | — | WO | disclosed |
| EP-0973534-A1 | PHARMACEUTICAL COMPOSITIONS HAVING APPETITE SUPPRESSANT ACTIVITY | CSIR (ZA) | 2000-01-26 | — | — | EP | disclosed |
| WO-1998046243-A2 | PHARMACEUTICAL COMPOSITIONS HAVING APPETITE SUPPRESSANT ACTIVITY | CSIR (ZA) | 1998-10-22 | — | — | WO | disclosed |
| WO-1998024792-A1 | ANTICOAGULANT GLYCOSIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024792-A1 | ANTICOAGULANT GLYCOSIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 1998-06-11 | — | — | WO | disclosed |
| EP-0730601-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTIONS | WASHINGTON UNIVERSITY (US) | 1996-09-11 | — | — | EP | disclosed |
| EP-0505573-B1 | PROCESS FOR PRODUCING D-ALTROSE | JAPAN TOBACCO INC (JP) | 1996-03-27 | — | — | EP | disclosed |
| WO-1995014028-A9 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTIONS | — | 1995-08-10 | — | — | WO | disclosed |
| WO-1995014028-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTIONS | WASHINGTON UNIVERSITY (US) | 1995-05-26 | — | — | WO | disclosed |
| US-5410038-A | method of preparing D-altrose | JAPAN TOBACCO INC. (JP) | 1995-04-25 | — | — | US | disclosed |
| EP-0505573-A1 | PROCESS FOR PRODUCING D-ALTROSE | Japan Tobacco Inc. (JP) | 1992-09-30 | — | — | EP | disclosed |
| US-5066645-A | Antitumor agents | BRISTOL-MYERS COMPANY (US) | 1991-11-19 | — | — | US | disclosed |
| EP-0415453-A2 | Epipodophyllotoxin altroside derivatives | Bristol-Myers Squibb Company (US) | 1991-03-06 | — | — | EP | disclosed |
| US-4593090-A | Containing perhydrofuran or pyran ring structure | GOGO KIMURA (JP) | 1986-06-03 | — | — | US | disclosed |
| EP-0067019-B1 | NOVEL NITROSOUREA COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Kimura, Goro (JP) | 1986-03-19 | — | — | EP | disclosed |
| EP-0067019-A1 | Novel nitrosourea compound, method for preparing same, and pharmaceutical composition containing same | Kimura, Goro (JP) | 1982-12-15 | — | — | EP | disclosed |
| US-4350811-A | Chiral sugar complexes | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1982-09-21 | — | — | US | disclosed |
| EP-0002046-B1 | PROCESS FOR THE PREPARATION OF (1S,2S,6R)-2-METHYL-3,7-DIOXABICYCLO(4,1,0)HEPTAN-4-OL AND ITS METHYL ETHER | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1982-02-10 | — | — | EP | disclosed |
| EP-0002046-B1 | PROCESS FOR THE PREPARATION OF (1S,2S,6R)-2-METHYL-3,7-DIOXABICYCLO(4,1,0)HEPTAN-4-OL AND ITS METHYL ETHER | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1982-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130752-A1 | SYNTHESIS OF CYCLIC CARBONATES | CA2, SCO2, CA7 | LGALS3 4339/4885LGALS1 4216/4885LGALS9 2958/4885 |
| US-20190134216-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | LGALS3 1610/4885LGALS1 2642/4885LGALS9 1366/4885 |
| US-20180185523-A1 | METHOD FOR IMAGING ARTHRITIS | SYVN1, SSTR3, ACKR3 | LGALS3 172/4885LGALS1 941/4885LGALS9 486/4885 |
| US-20120232256-A1 | PROCESS FOR PRODUCING 1,2-TRANS-GLYCOSIDE COMPOUND | ADH1C, ADH1A, CYP2E1 | LGALS3 2978/4885LGALS1 1686/4885LGALS9 1911/4885 |
| US-20120053313-A1 | POLYMER COMPOSITION | UACA, CRYAA, CRYZ | LGALS3 1575/4885LGALS1 641/4885LGALS9 1126/4885 |
| US-20130035414-A1 | HIGH REFRACTIVE INDEX POLYMER COMPOSITION FOR OPTHALMIC APPLICATIONS | NR1I3, NR1I2, LBR | LGALS3 1838/4885LGALS1 456/4885LGALS9 819/4885 |
| US-20130266595-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD79B, BCL6B, DRD1 | LGALS3 2822/4885LGALS1 2394/4885LGALS9 2951/4885 |
| US-20040029851-A1 | Mitochondrially targeted antioxidants | GPX1, TXNRD2, GSR | LGALS3 1449/4885LGALS1 2015/4885LGALS9 1798/4885 |
| US-20160144052-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD79B, BCR, GABRA3 | LGALS3 2754/4885LGALS1 2989/4885LGALS9 1834/4885 |
| US-20140302066-A1 | PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES | DRD2, DRD3, SBDS | LGALS3 4070/4885LGALS1 4711/4885LGALS9 4296/4885 |
| US-20170298137-A1 | PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES | DRD2, DRD3, SBDS | LGALS3 4070/4885LGALS1 4711/4885LGALS9 4296/4885 |
| US-20240109916-A1 | CYTOTOXIC AGENTS | MKI67, TP53, NFATC1 | LGALS3 2118/4885LGALS1 1964/4885LGALS9 3017/4885 |
| US-20260062633-A1 | EMULSION | C5, PHOSPHO1, PFKFB1 | LGALS3 1275/4885LGALS1 832/4885LGALS9 1664/4885 |
| US-20220288221-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | LGALS3 1610/4885LGALS1 2642/4885LGALS9 1366/4885 |
| US-20090163477-A1 | PHTHALAZINONE DERIVATIVES | PARP1, PARP2, PARP11 | LGALS3 4101/4885LGALS1 3682/4885LGALS9 4580/4885 |
| US-20140303367-A1 | Methods for Synthesizing Molybdopterin Precursor Z Derivatives | MTHFD2, ADH1B, DPYD | LGALS3 4736/4885LGALS1 4712/4885LGALS9 4287/4885 |
| US-20130317237-A1 | SYNTEHSIS OF CYCLIC CARBONATES | CA12, SUCLA2, LMNA | LGALS3 2089/4885LGALS1 1720/4885LGALS9 2035/4885 |
| US-20140378442-A1 | PHTHALAZINONE DERIVATIVES | NR0B1, NR0B2, NR2E1 | LGALS3 4221/4885LGALS1 2781/4885LGALS9 4247/4885 |
| US-20210284613-A1 | RADIOLABELLED COMPOUND | PARP3, PARP2, PARP1 | LGALS3 1132/4885LGALS1 1629/4885LGALS9 1030/4885 |
| US-20160129013-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | QDPR, SBDS, DNPEP | LGALS3 3736/4885LGALS1 4207/4885LGALS9 2225/4885 |
| US-10287220-B2 | Fluorination method | F13B, PPARG, PGC | LGALS3 952/4885LGALS1 1424/4885LGALS9 1241/4885 |
| US-11466032-B2 | Cytotoxic agents | MKI67, TP53, NFATC1 | LGALS3 2118/4885LGALS1 1964/4885LGALS9 3017/4885 |
| US-20070191349-A1 | C8, c8' linked 5-oxo-1,2,3,11a-tetrahydro-5h-pyrrolo[2,1-c][1,4] benzodiazepine dimers with 1h-pyrrole-dicarboxylic acid amide linkers and oligomeric analogs therof as well as related compounds for the treatment of proliferative diseases | TSPO, GABRD, BCOR | LGALS3 4803/4885LGALS1 4764/4885LGALS9 4816/4885 |
| US-20200345861-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | CD79B, BCL6B, BCL6 | LGALS3 3180/4885LGALS1 3599/4885LGALS9 1791/4885 |
| US-20210371413-A1 | POLYCYCLIC AMIDES AS CYTOTOXIC AGENTS | PBRM1, NFATC1, ACIN1 | LGALS3 4165/4885LGALS1 3872/4885LGALS9 4417/4885 |
| US-20210171637-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | HRH3, H1-3, CD274 | LGALS3 568/4885LGALS1 2094/4885LGALS9 1295/4885 |
| US-11690918-B2 | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates | CD22, CD2, CD2BP2 | LGALS3 1065/4885LGALS1 1398/4885LGALS9 460/4885 |
| US-20040254149-A1 | 3, 4-Methylenedioxy-substituted chalcones as therapeutic agents | OXER1, CCNO, CCNB3 | LGALS3 1959/4885LGALS1 2581/4885LGALS9 4255/4885 |
| US-11524969-B2 | Pyrrolobenzodiazepines and conjugates thereof as antitumour agents | PBRM1, HDAC6, NPM1 | LGALS3 3197/4885LGALS1 4031/4885LGALS9 3688/4885 |
| US-20190218291-A1 | COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE | ERBB2, ERBB3, AXL | LGALS3 255/4885LGALS1 324/4885LGALS9 229/4885 |
| US-20140323726-A1 | Methods for synthesizing molybdopterin precursor Z derivatives | MTHFD2, ADH1B, DPYD | LGALS3 4736/4885LGALS1 4712/4885LGALS9 4287/4885 |
| US-20060100265-A1 | 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents | TXNRD1, TXNRD3, TXNRD2 | LGALS3 4077/4885LGALS1 3726/4885LGALS9 4409/4885 |
| US-20060079528-A1 | (E)-3-(1,3-Benzoxazol-2-yl)-N-hydroxy-2-propenamide; Methyl (E)-3-(2-quinolinyl)-2-propenoate; histone deacetylase inhibitors; inflammatory disease; cancer | HDAC1, HDAC11, HDAC5 | LGALS3 3420/4885LGALS1 3961/4885LGALS9 3978/4885 |
| US-10576164-B2 | Pyrrolobenzodiazepines and conjugates thereof | CHRM1, NPSR1, CHRM4 | LGALS3 3462/4885LGALS1 4533/4885LGALS9 3185/4885 |
| US-20200399365-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | SBDS, DCTD, DRD1 | LGALS3 4474/4885LGALS1 4509/4885LGALS9 3223/4885 |
| US-20150307541-A1 | WATER-SOLUBLE PHOTOCHROMIC MOLECULES | SLC2A3, CCND3, MRPS23 | LGALS3 215/4885LGALS1 828/4885LGALS9 2612/4885 |
| US-20070191309-A1 | Pyrrolobenzodiazepines as key intermediates in the synthesis of dimeric cytotoxic pyrrolobenzodiazepines | CBR3, CBR1, CYCS | LGALS3 4373/4885LGALS1 4750/4885LGALS9 4454/4885 |
| US-20170226124-A1 | PHTHALAZINONE DERIVATIVES | NR0B1, NR0B2, NR2E1 | LGALS3 4380/4885LGALS1 3053/4885LGALS9 4359/4885 |
| US-20060058282-A1 | Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors | HDAC1, HDAC7, HDAC11 | LGALS3 4046/4885LGALS1 3527/4885LGALS9 3477/4885 |
| US-20090281086-A1 | 2 -OXYHETEROARYLAMIDE DERIVATIVES AS PARP INHIBITORS | PARP2, PARP3, PARP11 | LGALS3 4649/4885LGALS1 4455/4885LGALS9 4769/4885 |
| US-12398162-B2 | Guanine analogs as telomerase substrates and telomere length affectors | TERT, POT1, TERF2 | LGALS3 2578/4885LGALS1 1788/4885LGALS9 2878/4885 |
| US-20060172019-A1 | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders | CNR2, CNR1, GPER1 | LGALS3 2214/4885LGALS1 2160/4885LGALS9 2578/4885 |
| US-20180169258-A1 | PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES | CD22, CD2, CD2BP2 | LGALS3 1133/4885LGALS1 1403/4885LGALS9 518/4885 |
| US-20050107445-A1 | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors | HDAC1, HDAC11, HDAC3 | LGALS3 4614/4885LGALS1 4181/4885LGALS9 4502/4885 |
| US-20180092986-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES | CD22, SBDS, CD2 | LGALS3 3313/4885LGALS1 3170/4885LGALS9 2054/4885 |
| US-20060135770-A1 | PARP inhibitors | PARP2, PARP1, PARP3 | LGALS3 4077/4885LGALS1 3918/4885LGALS9 4383/4885 |
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | LGALS3 1076/4885LGALS1 2150/4885LGALS9 1101/4885 |
| US-20040092598-A1 | Carbamic acid compounds comprising an amide linkage as hdac inhibitors | HDAC1, HDAC11, HDAC3 | LGALS3 4589/4885LGALS1 4283/4885LGALS9 4646/4885 |
| US-20100113425-A1 | PYRROLOBENZODIAZEPINES | CNR1, MC3R, NPSR1 | LGALS3 3390/4885LGALS1 4770/4885LGALS9 3134/4885 |
| US-10561739-B2 | Targeted pyrrolobenzodiazapine conjugates | QDPR, SBDS, DNPEP | LGALS3 3736/4885LGALS1 4207/4885LGALS9 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.